

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number
WO 2004/043367 A2

(51) International Patent Classification⁷:

A61K

RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2003/035321

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

6 November 2003 (06.11.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/424,250 6 November 2002 (06.11.2002) US

(71) Applicant (for all designated States except US): BRISTOL-MYERS SQUIBB COMPANY [US/US]; P. O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BARBOSA, Joseph, [US/US]; 2 Big Top Drive, Lambertville, NJ 08530 (US). PITTS, William J, [US/US]; 1 Gladiola Circle, Newtown, PA 18940 (US). GUO, Junqing [CN/US]; 11 Burton Circle, Princeton, NJ 08540 (US).

(74) Agents: DUNCAN, Laurelee et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations


Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/043367 A2

(54) Title: FUSED HETEROCYCLIC COMPOUNDS AND USE THEREOF



(57) Abstract: Fused heterocyclic compounds of the following Formula (I) wherein R₁?¹, R₂?², R₅?⁵, Z, J₁?¹ and J₂?² are described herein, and analogs thereof are provided which are useful in treating leukocyte activation-associated disorders.

Fused Heterocyclic Compounds and Use Thereof

This application claims priority from U.S. provisional application serial number 60.424,250 filed November 6, 2002, the entirety of which is incorporated 5 herein by reference.

Field of the Invention

The present invention relates to fused heterocyclic compounds, pharmaceutical compositions containing these compounds, and the use of these 10 compounds in the treatment of leukocyte activation-associated disorders.

Background of the Invention

The immune system plays an important role in host defense. In the treatment of leukocyte activation-associated disorders is often desirable to attenuate 15 the immune response. Such disorders include the immune response incurred by transplantation or diseases improved by decreased T-cell activation and proliferation. It is accepted that agents that inhibit T-cell proliferation may be useful in the treatment of the aforementioned disorders.

A number of agents demonstrate clinical or therapeutic utility by 20 attenuating or modulating the immune system. Such agents include Cyclosporin A (“CsA”), azathioprine, tacrolimus, sirolimus and mycophenolate mofetil. However, these agents often demonstrate a relatively high incidence (25 to > 50%) of multiple unique liabilities during clinical or therapeutic use. For example, CsA therapy is associated with nephrotoxicity, azathioprine therapy is associated with leukopenia, 25 and tacrolimus therapy is associated with undesirable effects on the central nervous system. Also, sirolimus therapy is associated with hypertension, hyperlipidemia and hypercholesterolemia, and mycophenolate mofetil therapy is associated with diarrhea.


The overproduction of cytokines, such as TNF- α , is also implicated in a wide variety of leukocyte activation-associated disorders, including rheumatoid arthritis 30 (RA), psoriasis, multiple sclerosis, inflammatory bowel disease, endotoxin shock, osteoporosis, Alzheimer’s disease and congestive heart failure, among others. *See e.g.*, Henry *et al.*, *Drugs Fut.*, 24:1345-1354 (1999); Salituro *et al.*, *Curr. Med. Chem.*,

6:807-823 (1999). There is convincing evidence in human patients that cytokine protein antagonists can provide treatment for these disorders. *See e.g.*, Rankin *et al.*, *Br. J. Rheumatol.*, 34:334-342 (1995) (monoclonal antibody to TNF- α -- Enbrel®); and Moreland *et al.*, *Ann. Intern. Med.*, 130:478-486 (1999) (soluble TNF- α receptor-5 Fc fusion protein -- etanercept). Accordingly, it is accepted that agents demonstrating TNF- α inhibitory activity are useful for the treatment of leukocyte activation-associated disorders.

As none of the current treatments provide complete relief of symptoms and are often associated with various liabilities, new agents and improved methods for 10 treating leukocyte activation-associated disorders are needed.

Summary of the Invention

The present invention provides novel fused heterocyclic compounds of the 15 following Formula (I), their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, for use in treating leukocyte activation-associated disorders:




20 wherein:

R^1 is hydrogen or alkyl;

R^2 is

- (a) heteroaryl or heterocyclo, either of which may be optionally independently substituted with one to three groups selected from T^1 , T^2 and/or T^3 ;
- (b) aryl substituted with one to three groups selected from T^1 , T^2 and/or T^3 provided that at least one of T^1 , T^2 and/or T^3 is other than H; or
- (c) aryl fused to a heteroaryl or heterocyclo ring forming a fused ring system bound to N^* through the aryl wherein the fused ring system may be

optionally independently substituted with one to three groups selected from T¹, T² and/or T³;
 provided that R² is not



5 Z is -NR³R⁴, -NR³SO₂R⁶, OR⁴, SR⁴, haloalkyl or halogen;
 J¹ is O, S, S(O), S(O)₂ or optionally substituted C₁₋₃ alkylene;
 J² is carbonyl or optionally substituted C₁₋₃ alkylene, provided that J¹ and J² taken
 together do not form an alkylene chain of greater than 4 carbon atoms;
 R³ and R⁴ are independently H, alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl,
 10 (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or
 (heterocyclo)alkyl, any of which may be optionally independently substituted
 where valance allows with one to three groups T⁴, T⁵ and/or T⁶,
 or R³ and R⁴ may be taken together with the nitrogen atom to which they are attached
 to form a heterocyclo or heteroaryl ring, either of which is optionally
 15 independently substituted where valance allows with one to three groups
 independently selected from T⁴, T⁵ and/or T⁶;

R⁵ is

(i) H, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, aryl,
 (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or
 20 (heteroaryl)alkyl, any of which may be independently substituted
 where valance allows with one to three groups T⁷, T⁸ and/or T⁹; or
 (ii) -C(O)_tR⁷, -C(O)-C(O)-C(O)OR⁷ or -SO₂R⁸;

R⁶ is alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl,
 (cycloalkyl)alkyl, heterocyclo, or (heterocyclo)alkyl, any of which may be
 25 optionally independently substituted where valance allows with one to three
 groups T⁴, T⁵ and/or T⁶;

R⁷ is

(i) H, alkyl, alkenyl, heterocyclo, (heterocyclo)alkyl, (hydroxy)alkyl, (alkoxy)alkyl, (aryloxy)alkyl, heteroaryl, aryl or (aryl)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T⁷, T⁸ and/or T⁹; or

5 (ii) -NR⁹R¹⁰ or (NR⁹R¹⁰)alkyl;

R⁸ is

(i) alkyl, alkenyl, heterocyclo, (heterocyclo)alkyl, (hydroxy)alkyl, (alkoxy)alkyl, (aryloxy)alkyl, heteroaryl, aryl or (aryl)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T⁷, T⁸ and/or T⁹; or

10 (ii) -NR⁹R¹⁰ or (NR⁹R¹⁰)alkyl;

R⁹ and R¹⁰ are independently H, alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or (heterocyclo)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T⁷, T⁸ and/or T⁹;

15 T¹-T⁹ are each independently

(i) alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently substituted by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl, (heteroaryl)alkyl, -OT¹⁰, -SH, -ST¹⁰, -C(O)_tH, -C(O)_tT¹⁰, -O-C(O)¹⁰, T¹⁷C(O)_tN(T¹¹)T¹⁰, -SO₃H, -S(O)_tT¹⁰, S(O)_tN(T¹¹)T¹⁰, -T¹²-NT¹⁴T¹⁵, -T¹²-N(T¹¹)-T¹³-NT¹⁴T¹⁵, -T¹²-N(T¹⁶)-T¹⁵-T¹⁰ and -T¹²-N(T¹⁶)-T¹³-H; or

20 (ii) halo, cyano, nitro, OH, oxo, -SH, amino, -OT¹⁰, -ST¹⁰, -C(O)_tH, -C(O)_tT¹⁰, -O-C(O)T¹⁰, T¹⁷C(O)_tN(T¹¹)T¹⁰, -SO₃H, -S(O)_tT¹⁰, S(O)_tN(T¹¹)T¹⁰, -T¹²-NT¹⁴T¹⁵, -T¹²-N(T¹¹)-T¹³-NT¹⁴T¹⁵, -T¹²-N(T¹⁶)-T¹⁵-T¹⁰ or -T¹²-N(T¹⁶)-T¹³-H;

25 t is 1 or 2;

T^{10} is alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl; T^{12} and T^{13} are each independently a single bond, $-T^{17}-S(O)-T^{18}-$, $-T^{17}-C(O)-T^{18}-$, $-T^{17}-C(S)-T^{18}-$, $-T^{17}-O-T^{18}-$, $-T^{17}-S-T^{18}-$, $-T^{17}-O-C(O)-T^{18}-$, $-T^{17}-C(O)-T^{18}-$, $-T^{17}-C(=NT^{19})-T^{18}-$ or $-T^{17}-C(O)-C(O)-T^{18}-$; T^{11} , T^{14} , T^{15} , T^{16} and T^{19} are each independently

- (i) hydrogen, alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently substituted where valence permits by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl, (heteroaryl)alkyl, $-SH$, $-ST^{22}$, $-C(O)-H$, $-C(O)-T^{22}$, $-O-C(O)-T^{22}$ and $-S(O)-T^{22}$; or
- (ii) halo, cyano, nitro, OH, oxo, $-SH$, amino, $-OT^{22}$, $-ST^{22}$, $-C(O)-H$, $-C(O)-T^{22}$, $-O-C(O)-T^{22}$, $-SO_3H$ or $-S(O)-T^{22}$; or
- (iii) T^{14} and T^{15} may together be alkylene or alkenylene, completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is substituted with one or more groups listed in the description of T^{20} ; or
- (iv) T^{14} or T^{15} , together with T^{11} , may be alkylene or alkenylene completing a 3- to 8-membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is substituted with one or more groups listed in the description of T^{20} ; or
- (v) T^{14} and T^{15} or T^{11} and T^{16} together with the nitrogen atom to which they are attached may combine to form a group $-N=CT^{20}T^{21}$;

T^{17} and T^{18} are each independently a single bond, alkylene, alkenylene or alkynylene; T^{20} and T^{21} are each

(i) independently hydrogen, alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally 5 independently substituted where valence permits by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl, (heteroaryl)alkyl, —SH, —ST²², —C(O)_tH, —C(O)_tT²², —O-C(O)T²² and —S(O)_tT²²; or 10 (ii) halo, cyano, nitro, OH, oxo, —SH, amino, —OT²², —ST²², —C(O)_tH, —C(O)_tT²², —O-C(O)T²², —SO₃H, —S(O)_tT²², S(O)_tN(T¹¹)T²²,
15 T²² is alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl.

The following are definitions of the terms as used throughout this specification and claims. The initial definition provided for a group or term herein applies to that group or term throughout the present specification, individually or as part of another 20 group, unless otherwise indicated.

The terms "alk" or "alkyl" refer to straight or branched chain hydrocarbon groups having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, etc. Lower alkyl groups, that is, alkyl groups of 1 to 6 carbon atoms, are generally most 25 preferred.

The term "substituted alkyl" refers to alkyl groups substituted with one or more groups listed in the definition of T¹-T⁹, preferably selected from halo, cyano, O-R₁₁, S-R₁₁, NR₁₂R₁₃, nitro, cycloalkyl, substituted cycloalkyl, oxo, aryl, substituted aryl, heterocyclo, heteroaryl, CO₂R₁₁, S(O)R₁₁, SO₂R₁₁, SO₃R₁₁, SO₂NR₁₂R₁₃, 30 C(O)NR₁₂R₁₃, C(O)alkyl and C(O)H.

The term "alkylene" refers to a straight chain bridge of 1 to 4 carbon atoms connected by single bonds (e.g., -(CH₂)_x- wherein x is 1 to 5), which may be substituted with one or more groups listed in the definition of T¹-T⁹.

5 The term "alkenyl" refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms, preferably 2 to 4 carbon atoms, and at least one double carbon to carbon bond (either cis or trans), such as ethenyl.


10 The term "substituted alkenyl" refers to an alkenyl group as defined above substituted with one or more groups listed in the definition of T¹-T⁹, preferably selected from halo, cyano, O-R₁₁, S-R₁₁, NR₁₂R₁₃, nitro, cycloalkyl, substituted cycloalkyl, oxo, aryl, substituted aryl, heterocyclo, heteroaryl, CO₂R₁₁, S(O)R₁₁, SO₂R₁₁, SO₃R₁₁, SO₂NR₁₂R₁₃, C(O)NR₁₂R₁₃, C(O)alkyl and C(O)H.

The term "alkynyl" refers to straight or branched chain hydrocarbon group having 2 to 12 carbon atoms and one, two or three triple bonds, preferably 2 to 6 carbon atoms and one triple bond.

15 The term "substituted alkynyl" refers to an alkynyl group as defined above substituted with one or more groups listed in the definition of T¹-T⁹, preferably selected from halo, cyano, O-R₁₁, S-R₁₁, NR₁₂R₁₃, nitro, cycloalkyl, substituted cycloalkyl, oxo, aryl, substituted aryl, heterocyclo, heteroaryl, CO₂R₁₁, S(O)R₁₁, SO₂R₁₁, SO₃R₁₁, SO₂NR₁₂R₁₃, C(O)NR₁₂R₁₃, C(O)alkyl and C(O)H.

20 The term "carbonyl" refers to C=O, which may also be designated as C(O).


The group -C(O)_tX refers to C(O)X where t is 1 and the structure



where t is 2.

The term "halo" refers to chloro, bromo, fluoro and iodo.


25 The term "cycloalkyl" refers to saturated and partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 3 to 7 carbons, forming the ring and which may be fused to 1 or 2 aromatic or heterocyclo rings, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, 30 cyclohexenyl,



The term "substituted cycloalkyl" refers to such cycloalkyl group as defined above substituted with one or more groups listed in the definition of T¹-T⁹ preferably selected from halogen, nitro, alkyl, substituted alkyl, alkenyl, cyano, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocyclo, heteroaryl, oxo, OR₁₁, CO₂R₁₁, C(O)NR₁₂R₁₃, OC(O)R₁₁, OC(O)OR₁₁, OC(O)NR₁₂R₁₃, OCH₂CO₂R₁₁, C(O)R₁₁, NR₁₂R₁₃, NR₁₄C(O)R₁₁, NR₁₄C(O)OR₁₁, NR₁₄C(O)C(O)OR₁₁, NR₁₄C(O)C(O)NR₁₂R₁₃, NR₁₄C(O)C(O)alkyl, NR₁₄C(NCN)OR₁₁, NR₁₄C(O)NR₁₂R₁₃, NR₁₄C(NCN)NR₁₂R₁₃, NR₁₄C(NR₁₅)NR₁₂R₁₃, NR₁₄SO₂NR₁₂R₁₃, NR₁₄SO₂R₁₁, SR₁₁, S(O)R₁₁, SO₂R₁₁, SO₃R₁₁, SO₂NR₁₂R₁₃, NHOR₁₁, NR₁₄NR₁₂R₁₃, N(COR₁₁)OR₁₄, N(CO₂R₁₁)OR₁₄, C(O)NR₁₄(CR₁₆R₁₁)_rR₁₁, CO(CR₁₆R₁₇)_pO(CR₁₂R₁₃)_qCO₂R₁₁, CO(CR₁₆R₁₇)_rOR₁₁, CO(CR₁₆R₁₇)_pO(CR₁₈R₁₃)_qR₁₁, CO(CR₁₆R₁₇)_rNR₁₂R₁₃, OC(O)O(CR₁₆R₁₇)_mNR₁₂R₁₃, OC(O)N(CR₁₆R₁₇)_rR₁₁, O(CR₁₆R₁₇)_mNR₁₂R₁₃, NR₁₄C(O)(CR₁₆R₁₇)_rR₁₁, NR₁₄C(O)(CR₁₆R₁₇)_rOR₁₁, NR₁₄C(=NC)(CR₁₆R₁₇)_rR₁₁, NR₁₄CO(CR₁₆R₁₇)_rNR₁₂R₁₃, NR₁₄(CR₁₆R₁₇)_mOR₁₁, NR₁₄(CR₁₆R₁₇)_rCO₂R₁₁, NR₁₄(CR₁₆R₁₇)_mNR₁₂R₁₃, NR₁₄(CR₁₆R₁₇)_nSO₂(CR₁₈R₁₃)_qR₁₁, CONR₁₄(CR₁₆R₁₇)_nSO₂(CR₁₈R₁₃)_qR₁₁, SO₂NR₁₄(CR₁₆R₁₇)_nCO(CR₁₈R₁₉)_qR₁₁ and SO₂NR₁₄(CR₁₆R₁₇)_mOR₁₁.

The terms "ar" or "aryl" refer to aromatic homocyclic (i.e., hydrocarbon) mono-, bi- or tricyclic ring-containing groups preferably having 6 to 12 members such


as phenyl, naphthyl and biphenyl, as well as such rings fused to a cycloalkyl, cycloalkenyl, heterocyclo, or heteroaryl ring. Examples include:



The term "substituted aryl" refers to such aryl groups as defined above substituted with one or more groups listed in the definition of T^1 - T^9 , preferably selected from halogen, nitro, alkyl, substituted alkyl, alkenyl, cyano, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocyclo, heteroaryl, o xo, OR_{11} , CO_2R_{11} , $C(O)NR_{12}R_{13}$, $OC(O)R_{11}$, $OC(O)OR_{11}$, $OC(O)NR_{12}R_{13}$, $OCH_2CO_2R_{11}$, $C(O)R_{11}$, $NR_{12}R_{13}$, $NR_{14}C(O)R_{11}$, $NR_{14}C(O)OR_{11}$, $NR_{14}C(O)C(O)OR_{11}$, $NR_{14}C(O)C(O)NR_{12}R_{13}$, $NR_{14}C(O)C(O)alkyl$, $NR_{14}C(NCN)OR_{11}$, $NR_{14}C(O)NR_{12}R_{13}$, $NR_{14}C(NCN)NR_{12}R_{13}$, $NR_{14}C(NR_{15})NR_{12}R_{13}$, $NR_{14}SO_2NR_{12}R_{13}$, $NR_{14}SO_2R_{11}$, SR_{11} , $S(O)R_{11}$, SO_2R_{11} , SO_3R_{11} , $SO_2NR_{12}R_{13}$, $NHOR_{11}$, $NR_{14}NR_{12}R_{13}$, $N(COR_{11})OR_{14}$, $N(CO_2R_{11})OR_{14}$, $C(O)NR_{14}(CR_{16}R_{17})_rR_{11}$, $CO(CR_{16}R_{17})_pO(CR_{12}R_{13})_qCO_2R_{11}$, $CO(CR_{16}R_{17})_rOR_{11}$, $CO(CR_{16}R_{17})_pO(CR_{18}R_{19})_qR_{11}$, $CO(CR_{16}R_{17})_rNR_{12}R_{13}$, $OC(O)O(CR_{16}R_{17})_mNR_{12}R_{13}$, $OC(O)N(CR_{16}R_{17})_rR_{11}$, $O(CR_{16}R_{17})_mNR_{12}R_{13}$, $NR_{14}C(O)(CR_{16}R_{17})_rR_{11}$, $NR_{14}C(O)(CR_{16}R_{17})_rOR_{11}$, $NR_{14}C(=NC)(CR_{16}R_{17})_rR_{11}$, $NR_{14}CO(CR_{16}R_{17})_rNR_{12}R_{13}$, $NR_{14}(CR_{16}R_{17})_mOR_{11}$, $NR_{14}(CR_{16}R_{17})_rCO_2R_{11}$, $NR_{14}(CR_{16}R_{17})_mNR_{12}R_{13}$, $NR_{14}(CR_{16}R_{17})_nSO_2(CR_{18}R_{19})_qR_{11}$, $CONR_{14}(CR_{16}R_{17})_nSO_2(CR_{18}R_{19})_qR_{11}$, $SO_2NR_{14}(CR_{16}R_{17})_mOR_{11}$ as well as pentafluorophenyl.

The terms "heterocycle", "heterocyclic", "heterocyclic group" or "heterocyclo" refer to fully saturated or partially unsaturated cyclic groups (for example, 3 to 13 member monocyclic, 7 to 17 member bicyclic, or 10 to 20 member tricyclic ring systems, preferably containing a total of 3 to 10 ring atoms) which have at least one


heteroatom in at least one carbon atom-containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1, 2, 3 or 4 heteroatoms selected from nitrogen atoms, oxygen atoms and/or sulfur atoms, where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized. The heterocyclic group may be attached at any heteroatom or carbon atom of the ring or ring system. The rings of multi-ring heterocycles may be either fused, bridged and/or joined through one or more spiro unions. Exemplary heterocyclic groups include




The terms "substituted heterocycle" or "substituted heterocyclo" and the like refer to such heterocyclo groups as defined above substituted with one or more groups listed in the definition of T^1-T^9 , preferably selected from halogen, nitro, alkyl, substituted alkyl, alkenyl, cyano, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocyclo, heteroaryl, oxo, OR_{11} , CO_2R_{11} , $C(O)NR_{12}R_{13}$, $OC(O)R_{11}$, $OC(O)OR_{11}$, $OC(O)NR_{12}R_{13}$, $OCH_2CO_2R_{11}$, $C(O)R_{11}$, $NR_{12}R_{13}$, $NR_{14}C(O)R_{11}$, $NR_{14}C(O)OR_{11}$, $NR_{14}C(O)C(O)OR_{11}$, $NR_{14}C(O)C(O)NR_{12}R_{13}$, $NR_{14}C(O)C(O)alkyl$, $NR_{14}C(NCN)OR_{11}$, $NR_{14}C(O)NR_{12}R_{13}$, $NR_{14}C(NCN)NR_{12}R_{13}$, $NR_{14}C(NR_{15})NR_{12}R_{13}$,

NR₁₄SO₂NR₁₂R₁₃, NR₁₄SO₂R₁₁, SR₁₁, S(O)R₁₁, SO₂R₁₁, SO₃R₁₁, SO₂NR₁₂R₁₃, NHOR₁₁, NR₁₄NR₁₂R₁₃, N(COR₁₁)OR₁₄, N(CO₂R₁₁)OR₁₄, C(O)NR₁₄(CR₁₆R₁₇)_rR₁₁, CO(CR₁₆R₁₇)_pO(CR₁₈R₁₃)_qCO₂R₁₁, CO(CR₁₆R₁₇)_rOR₁₁, CO(CR₁₆R₁₇)_pO(CR₁₈R₁₉)_qR₁₁, CO(CR₁₆R₁₇)_rNR₁₂R₁₃, OC(O)O(CR₁₆R₁₇)_mNR₁₂R₁₃, OC(O)N(CR₁₆R₁₇)_rR₁₁, 5 O(CR₁₆R₁₇)_mNR₁₂R₁₃, NR₁₄C(O)(CR₁₆R₁₇)_rR₁₁, NR₁₄C(O)(CR₁₆R₁₇)_rOR₁₁, NR₁₄C(=NC)(CR₁₆R₁₇)_rR₁₁, NR₁₄CO(CR₁₆R₁₇)_rNR₁₂R₁₃, NR₁₄(CR₁₆R₁₇)_mOR₁₁, NR₁₄(CR₁₆R₁₇)_rCO₂R₁₁, NR₁₄(CR₁₆R₁₇)_mNR₁₂R₁₃, NR₁₄(CR₁₆R₁₇)_nSO₂(CR₁₈R₁₃)_qR₁₁, CONR₁₄(CR₁₆R₁₇)_nSO₂(CR₁₈R₁₉)_qR₁₁, SO₂NR₁₄(CR₁₆R₁₇)_nCO(CR₁₈R₁₉)_qR₁₁ and SO₂NR₁₄(CR₁₆R₁₇)_mOR₁₁.

10 The term "heteroaryl" as used herein alone or as part of another group refers to a 5- 6- or 7- membered aromatic rings containing from 1 to 4 nitrogen atoms and/or 1 or 2 oxygen or sulfur atoms provided that the ring contains at least 1 carbon atom and no more than 4 heteroatoms. The heteroaryl ring is linked through an available carbon or nitrogen atom. Also included within the definition of heteroaryl are such rings fused to a 15 cycloalkyl, aryl, cycloheteroalkyl, or another heteroaryl ring. One, two, or three available carbon or nitrogen atoms in the heteroaryl ring can be optionally substituted with substituents listed in the definition of T¹-T⁹. Also an available nitrogen or sulfur atom in the heteroaryl ring can be oxidized. Examples of heteroaryl rings include



20



and the like.

The term "substituted heteroaryl" refers to such heteroaryl groups as defined above substituted on any available atom with one or more groups listed in the definition of T^1-T^9 , "preferably selected from" refers to such heterocyclo groups as defined above substituted with one or more groups listed in the definition of T^1-T^9 , preferably selected from halogen, nitro, alkyl, substituted alkyl, alkenyl, cyano, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocyclo, heteroaryl, oxo, OR_{11} , CO_2R_{11} , $C(O)NR_{12}R_{13}$, $OC(O)R_{11}$, $OC(O)OR_{11}$, $OC(O)NR_{12}R_{13}$, $OCH_2CO_2R_{11}$, $C(O)R_{11}$, $NR_{12}R_{13}$, $NR_{14}C(O)R_{11}$, $NR_{14}C(O)OR_{11}$, $NR_{14}C(O)C(O)OR_{11}$, $NR_{14}C(O)C(O)NR_{12}R_{13}$, $NR_{14}C(O)C(O)alkyl$, $NR_{14}C(NCN)OR_{11}$, $NR_{14}C(O)NR_{12}R_{13}$, $NR_{14}C(NCN)NR_{12}R_{13}$, $NR_{14}C(NR_{15})NR_{12}R_{13}$, $NR_{14}SO_2NR_{12}R_{13}$, $NR_{14}SO_2R_{11}$, SR_{11} , $S(O)R_{11}$, SO_2R_{11} , SO_3R_{11} , $SO_2NR_{12}R_{13}$, $NHOR_{11}$, $NR_{14}NR_{12}R_{13}$, $N(COR_{11})OR_{14}$, $N(CO_2R_{11})OR_{14}$, $C(O)NR_{14}(CR_{16}R_{17})_pR_{11}$, $CO(CR_{16}R_{17})_pO(CR_{12}R_{13})_qCO_2R_{11}$,

CO(CR₁₆R₁₇)_rOR₁₁, CO(CR₁₆R₁₇)_pO(CR₁₈R₁₉)_qR₁₁, CO(CR₁₆R₁₇)_rNR₁₂R₁₃,
 OC(O)O(CR₁₆R₁₇)_mNR₁₂R₁₃, OC(O)N(CR₁₆R₁₇)_rR₁₁, O(CR₁₆R₁₇)_mNR₁₂R₁₃,
 NR₁₄C(O)(CR₁₆R₁₇)_rR₁₁, NR₁₄C(O)(CR₁₆R₁₇)_rOR₁₁, NR₁₄C(=NC)(CR₁₆R₁₇)_rR₁₁,
 NR₁₄CO(CR₁₆R₁₇)_rNR₁₂R₁₃, NR₁₄(CR₁₆R₁₇)_mOR₁₁, NR₁₄(CR₁₆R₁₇)_rCO₂R₁₁,
 5 NR₁₄(CR₁₆R₁₇)_mNR₁₂R₁₃, NR₁₄(CR₁₆R₁₇)_nSO₂(CR₁₈R₁₉)_qR₁₁,
 CONR₁₄(CR₁₆R₁₇)_nSO₂(CR₁₈R₁₉)_qR₁₁,
 SO₂NR₁₄(CR₁₆R₁₇)_nCO(CR₁₈R₁₉)_qR₁₁ and SO₂NR₁₄(CR₁₆R₁₇)_mOR₁₁.

The variables employed in the preceding definitions are herein defined as follows:

10 R₁₁, R₁₄, and R₁₅ are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, C(O)alkyl, C(O)substituted alkyl, C(O)cycloalkyl, C(O) substituted cycloalkyl, C(O)aryl, C(O)substituted aryl, C(O)Oalkyl, C(O)Osubstituted alkyl, C(O)heterocyclo, C(O)heteroaryl, aryl, substituted aryl, heterocyclo and heteroaryl.

15 R₁₂ and R₁₃ are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, alkynyl, C(O)alkyl, C(O)substituted alkyl, C(O)cycloalkyl, C(O)substituted cycloalkyl, C(O)aryl, C(O)substituted aryl, C(O)Oalkyl, C(O)Osubstituted alkyl, C(O)heterocyclo, C(O)heteroaryl, S(O)₂alkyl, S(O)₂substituted alkyl, 20 S(O)₂cycloalkyl, S(O)₂substituted cycloalkyl, S(O)₂aryl, S(O)₂substituted aryl, S(O)₂heterocyclo, S(O)₂heteroaryl, aryl, substituted aryl, heterocyclo and heteroaryl, or R₁₂ and R₁₃ taken together with the nitrogen atom to which they are attached complete a heterocyclo or heteroaryl ring.

25 R₁₆ and R₁₈ are independently selected from hydrogen and alkyl or 1 to 4 carbons.

R₁₇ and R₁₉ are independently selected from hydrogen, alkyl of 1 to 4 carbons, and substituted alkyl or 1 to 4 carbons.

n is zero or an integer from 1 to 4.

m is an integer from 2 to 6.

30 p is an integer from 1 to 3.

q is zero or an integer from 1 to 3.

r is zero or an integer from 1 to 6.

The variables employed within the definition of T^1 - T^9 are defined herein as follows:

T^1 - T^9 are each independently

(i) alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently substituted by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, $-OT^{10}$, $-SH$, $-ST^{10}$, $-C(O)_tH$, $-C(O)_tT^{10}$, $-O-C(O)T^{10}$, $T^{17}C(O)_tN(T^{11})T^{10}$, $-SO_3H$, $-S(O)_tT^{10}$, $S(O)_tN(T^{11})T^{10}$, $-T^{12}$, $NT^{14}T^{15}$, $-T^{12}-N(T^{11})-T^{13}-NT^{14}T^{15}$, $-T^{12}-N(T^{16})-T^{15}-T^{10}$ and $-T^{12}-N(T^{16})-T^{13}-H$; or

(ii) halo, cyano, nitro, OH, oxo, $-SH$, amino, $-OT^{10}$, $-ST^{10}$, $-C(O)_tH$, $-C(O)_tT^{10}$, $-O-C(O)T^{10}$, $T^{17}C(O)_tN(T^{11})T^{10}$, $-SO_3H$, $-S(O)_tT^{10}$, $S(O)_tN(T^{11})T^{10}$, $-T^{12}-NT^{14}T^{15}$, $-T^{12}-N(T^{11})-T^{13}-NT^{14}T^{15}$, $-T^{12}-N(T^{16})-T^{15}-T^{10}$ or $-T^{12}-N(T^{16})-T^{13}-H$;

The variable t is 1 or 2.

T^{10} is alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl.

T^{12} and T^{13} are each independently a single bond, $-T^{17}-S(O)_tT^{18}-$, $-T^{17}-C(O)-T^{18}-$, $-T^{17}-C(S)-T^{18}-$, $-T^{17}-O-T^{18}-$, $-T^{17}-S-T^{18}-$, $-T^{17}-O-C(O)-T^{18}-$, $-T^{17}-C(O)_tT^{18}-$, $-T^{17}-C(=NT^{19})-T^{18}-$ or $-T^{17}-C(O)-C(O)-T^{18}-$.

T^{11} , T^{14} , T^{15} , T^{16} and T^{19} are each independently

(i) hydrogen, alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently substituted where valence permits by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl,

alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl, (heteroaryl)alkyl, —SH, —ST²², —C(O)_tH, —C(O)_tT²², —O—C(O)T²² and —S(O)_tT²²; or

5 (ii) halo, cyano, nitro, OH, oxo, —SH, amino, —OT²², —ST²², —C(O)_tH, —C(O)_tT²², —O—C(O)T²², —SO₃H, —S(O)_tT²² and S(O)_tN(T¹¹)T²²; or

10 (iii) T¹⁴ and T¹⁵ may together be alkylene or alkenylene, completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is substituted with one or more groups listed in the description of T²⁰; or

(iv) T¹⁴ or T¹⁵, together with T¹¹, may be alkylene or alkenylene completing a 3- to 8-membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is substituted with one or more groups listed in the description of T²⁰; or

15 (v) T¹⁴ and T¹⁵ or T¹¹ and T¹⁶ together with the nitrogen atom to which they are attached may combine to form a group —N=CT²⁰T²¹.

T¹⁷ and T¹⁸ are each independently a single bond, alkylene, alkenylene or alkynylene.

T²⁰ and T²¹ are each

20 (i) independently hydrogen, alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently substituted where valence permits by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl, (heteroaryl)alkyl, —SH, —ST²², —C(O)_tH, —C(O)_tT²², —O—C(O)T²² and —S(O)_tT²²; or

25 (ii) halo, cyano, nitro, OH, oxo, —SH, amino, —OT²², —ST²², —C(O)_tH, —C(O)_tT²², —O—C(O)T²², —SO₃H, —S(O)_tT²², S(O)_tN(T¹¹)T²²; or

T^{22} is alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl.

The term “optionally substituted” is intended to be synonymous with
5 “unsubstituted or substituted”. For example, an optionally substituted heterocycle is equivalent to an unsubstituted or substituted heterocycle.

“T-cell mediated diseases” refers to any disorder or disease state in which modulation of the activity of T-cells is implicated in a process which results in either a pathophysiological state or a process where the normal function of T-cells is
10 intended to be suppressed for therapeutic benefit. Examples of T-cell mediated disorders include transplant rejection, graft versus host disease, and autoimmune disorders, such as rheumatoid arthritis, multiple sclerosis, juvenile diabetes, asthma, and inflammatory bowel disease, T-cell mediated hypersensitivity diseases, ischemic or reperfusion injury, and T-cell proliferative disorders. T-cell mediated diseases are
15 included in the definition of “leukocyte activation-associated disorders” which is defined *infra*.

The compounds of Formula (I) in accordance with the present invention are employed, typically in the form of a pharmaceutical composition including a pharmaceutically acceptable carrier for the treatment of T-cell mediated disease. The
20 compounds employed for this purpose are typically administered in an amount from about 0.01 to 100 mg/kg/day.

The pharmaceutical compositions comprising at least one compound of Formula (I) may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to
25 the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.

The compounds of Formula (I) may be administered by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders;
30 sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by

inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents. The present compounds may, for example, be administered in a form suitable for immediate release or extended

5 release. Immediate release or extended release may be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps. The present compounds may also be administered in the form of liposomes.

10 Exemplary compositions for oral administration include suspensions which may contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which may contain, for example, microcrystalline cellulose, dicalcium

15 phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The present compounds may also be delivered through the oral cavity by sublingual and/or buccal administration. Molded tablets, compressed tablets or freeze-dried tablets are exemplary forms which may be used. Exemplary compositions include those

20 formulating the present compound(s) with fast dissolving diluents such as mannitol, lactose, sucrose and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (avicel) or polyethylene glycols (PEG). Such formulations may also include an excipient to aid mucosal adhesion such as hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC),

25 sodium carboxy methyl cellulose (SCMC), maleic anhydride copolymer (e.g., Gantrez), and agents to control release such as polyacrylic copolymer (e.g., Carbopol 934). Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.

Exemplary compositions for nasal aerosol or inhalation administration

30 include solutions in saline which may contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.

Exemplary compositions for parenteral administration include injectable solutions or suspensions which may contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or 5 wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.

Exemplary compositions for rectal administration include suppositories which may contain, for example, a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary 10 temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.

Exemplary compositions for topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene).

The effective amount of a compound employed in the present invention may be determined by one of ordinary skill in the art, and includes exemplary dosage 15 amounts for an adult human of from about 0.01 to 100 mg/kg of body weight of active compound per day, which may be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day. It will be understood that the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors including the activity of the specific 20 compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition. Preferred subjects for treatment include animals, most preferably 25 mammalian species such as humans, and domestic animals such as dogs, cats and the like, subject to inflammatory, immunological, or respiratory cell-associated disorders.

Compounds of Formula (I) include salts, prodrugs and solvates. The term "salt(s)", as employed herein, denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. Zwitterions (internal or inner salts) are included within the term "salt(s)" as used herein (and may be formed, for example, where the R 30 substituents comprise an acid moiety such as a carboxyl group). Also included herein are quaternary ammonium salts such as alkylammonium salts. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although

other salts are useful, for example, in isolation or purification steps which may be employed during preparation. Salts of the compounds of the Formula (I) may be formed, for example, by reacting a compound I with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in 5 an aqueous medium followed by lyophilization.

Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, 10 dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides, hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates, methanesulfonates, 2-naphthalenesulfonates, nicotinates, nitrates, oxalates, pectinates, persulfates, 15 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as those formed with sulfuric acid), sulfonates (such as those mentioned herein), tartrates, thiocyanates, toluenesulfonates, undecanoates, and the like.

Exemplary basic salts (formed, for example, where the R substituents comprise an acidic moiety such as a carboxyl group) include ammonium salts, alkali 20 metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as benzathines, dicyclohexylamines, hydrabamines, N-methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. The basic nitrogen-containing 25 groups may be quaternized with agents such as lower alkyl halides (e.g. methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g. decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.

30 Prodrugs and solvates of the compounds of the invention are also contemplated herein. The term "prodrug", as employed herein, denotes a compound which, upon administration to a subject, undergoes chemical conversion by metabolic

or chemical processes to yield a compound of Formula (I), or a salt and/or solvate thereof. Solvates of compounds of Formula (I) are preferably hydrates.

Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see:

- 5 a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and
Methods in Enzymology, Vol.42, p. 309-396, edited by K. Widder, *et al.* (Acamedic
Press, 1985);
- 10 b) A Textbook of Drug Design and Development, edited by Krosgaard-
Larsen and H. Bundgaard, Chapter 5, "Design and Application of Prodrugs," by H.
Bundgaard, pp. 113-191 (1991); and
- 15 c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992),
each of which is incorporated herein by reference.

Solvates (*e.g.*, hydrates) of the compounds of Formula (I) are also within the scope of the present invention. Methods of solvation are generally known in the art.

15 All stereoisomers of the present compounds, such as those which may exist due to asymmetric carbons on the R substituents of the compound of Formula (I), including enantiomeric and diastereomeric forms, are within the scope of this invention. Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the 20 present invention can have an S or R configuration as defined by the IUPAC 1974 Recommendations.

Preferred Compounds

25 Preferred compounds within the scope of the present invention include compounds of Formula (I) (above), their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, in which the substituents R¹, R², Z, J¹, J² and R⁵ are selected from the following:
R¹ is hydrogen or alkyl;
30 R² is

(a) heteroaryl (preferably thiazolyl or oxazolyl) optionally independently substituted with one to three groups selected from T^1 , T^2 and/or T^3 (preferably T^1 , T^2 , and/or T^3 are alkyl, haloalkyl, cyano, halogen, heteroaryl, $-C(O)_tT^{10}$, OT^{10} , $-S(O)_tN(T^{11})T^{10}$ or $-T^{17}NT^{11}T^{10}$); or

5 (b) aryl (preferably phenyl) substituted with one to three groups (preferably at least one group at the para position) selected from T^1 , T^2 and/or T^3 provided that at least one of T^1 , T^2 and/or T^3 is other than H (T^1 is preferably cyano, cyano, $C(O)_tT^{10}$, $S(O)_tN(T^{11})T^{10}$ or heteroaryl [heteroaryl is preferably imidazolyl, oxazolyl or thiazolyl, any of which is 10 optionally further substituted with one to two groups preferably selected from cyano, $C(O)_tT^{10}$, $S(O)_tN(T^{11})T^{10}$ and haloalkyl]); or

15 (c) aryl fused to a heteroaryl or heterocyclo ring forming a fused ring system bound to N^* through the aryl wherein the fused ring system (preferably tetrahydro indole bound through the aryl ring, quinolyl bound through the aryl ring [especially quinol-6-yl], quinazolinyl bound through the aryl ring [especially quinazolin-7-yl], cinnolinyl bound through the aryl ring [especially cinnolin-6-yl], isoquinolinyl bound through the aryl ring [especially isoquinol-6-yl], or phthalazinyl bound through the aryl ring [especially phthalazin-6-yl]). may be optionally independently 20 substituted with one to three groups selected from T^1 , T^2 and/or T^3 (T^1 , T^2 , and/or T^3 are preferably selected from halogen, OH, OT^{10} , alkyl, haloalkyl $-CO_tH$, $-CO_tT^{10}$ and $-C(O)NT^{11}T^{10}$);

Z is $-NR^3R^4$, $-NR^3SO_2R^6$, OR^4 , SR^4 , haloalkyl or halogen (preferably $-NR^3R^4$ or halogen, even more preferably $-NR^3R^4$);

25 J^1 is O, S, $S(O)$, $S(O)_2$ or optionally substituted C_{1-3} alkylene (preferably O, S or optionally substituted C_1 alkylene);

J^2 is carbonyl or optionally substituted C_{1-3} alkylene, provided that J^1 and J^2 taken together do not form an alkylene chain of greater than 4 carbon atoms;

30 R^3 and R^4 are independently H, alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or (heterocyclo)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T^4 , T^5 and/or T^6 (T^4 , T^5 and/or


T^6 are preferably selected from alkyl, hydroxyalkyl, halo, cyano, OH, oxo, cycloalkyl, cycloalkenyl, heterocyclo, heteroaryl, $-C(O)_t T^{10}$, $-C(O)_t H$, $-NHC(O)T^{10}$, $C(O)N(T^{11})(T^{10})$, OT^{10} , ST^{10} , $S(O)_3 H$, $S(O)_t T^{10}$, $S(O)_t N(T^{10})(T^{11})$, $T^{17}N(T^{14})(T^{15})$ and $T^{12}N(T^{16})-T^{15}-T^{10}$;

5 or R^3 and R^4 may be taken together with the nitrogen atom to which they are attached to form a heterocyclo or heteroaryl ring (preferably piperidyl, piperazinyl, morpholinyl, diazapanyl, 4 dioxa-8-azaspiro[4,5]decan-8-yl or pyrrolyl), either of which is optionally independently substituted where valance allows with one to three groups independently selected from T^4 , T^5 and/or T^6 [preferably 10 T^4 , T^5 and/or T^6 is selected from alkyl, hydroxyalkyl, halo, cyano, OH, oxo, cycloalkyl, cycloalkenyl, optionally substituted heterocyclo, optionally substituted heteroaryl, $-C(O)_t T^{10}$, $-C(O)_t H$, $-NHC(O)T^{10}$, $C(O)N(T^{11})(T^{10})$, OT^{10} , ST^{10} , $S(O)_3 H$, $S(O)_t T^{10}$, $S(O)_t N(T^{14})(T^{15})$, $T^{12}N(T^{14})(T^{15})$ and $T^{12}N(T^{16})-T^{15}-T^{10}$];

15 R^5 is

- (i) H, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo [preferably piperizolyl, morpholinyl, and indanyl],)alkyl, heteroaryl or (heteroaryl [preferably pyridyl, furanyl, thienyl, benzoisothiazolyl, and thiazolyl])alkyl, any of which may be independently substituted where valance allows with one to three groups T^7 , T^8 and/or T^9 [T^7 , T^8 and/or T^9 preferably selected from cyano, oxo, hydroxy, alkyl, halo, haloalkyl, $-OT^{10}$, $-C(O)_t N(T^{11})(T^{10})$, $-C(O)_t NH S(O)_t(T^{11})$, $-S(O)_t T^{10}$, $-S(O)_t N(T^{14})(T^{15})$, $T^{12}N(T^{14})(T^{15})$, $-C(O)_t T^{11}$, heterocyclo and heteroaryl, any of which 20 may be optionally substituted by one to three groups independently preferably selected from cyano, oxo, hydroxy, alkyl, halo, haloalkyl, and $-OT^{10}$]; or
- (ii) $-C(O)_t R^7$, $-C(O)-C(O)-C(O)OR^7$ or $-SO_2 R^8$;

25 30 Preferred compounds of the present invention include compounds of Formula (Ia)



their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, in which:

5 W is O or S;
 Y¹ is -NHT¹⁵ or OT¹⁰;
 Y² is alkyl, or haloalkyl;
 Z is -NR³R⁴ or halogen;
 J¹ is O or optionally substituted C₁₋₃ alkylene;

10 J² is carbonyl or optionally substituted C₁₋₃ alkylene, provided that J¹ and J² taken together do not form an alkylene chain of greater than 4 carbon atoms;
 R³ and R⁴ are independently H, alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or (heterocyclo)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T⁴, T⁵ and/or T⁶;

15 or R³ and R⁴ may be taken together with the nitrogen atom to which they are attached to form a heterocyclo or heteroaryl ring, either of which is optionally independently substituted where valance allows with one to three groups independently selected from T⁴, T⁵ and/or T⁶;

20 R⁵ is
 (i) H, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be independently substituted where valance allows with one to three groups T⁷, T⁸ and/or T⁹; or
 (ii) -C(O)_tR⁷, -C(O)-C(O)-C(O)OR⁷ or -SO₂R⁸;

25 R⁶ is alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo, or (heterocyclo)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T⁴, T⁵ and/or T⁶;

R⁷ is

5 (i) H, alkyl, alkenyl, heterocyclo, (heterocyclo)alkyl, (hydroxy)alkyl, (alkoxy)alkyl, (aryloxy)alkyl, heteroaryl, aryl or (aryl)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T⁷, T⁸ and/or T⁹; or

(ii) -NR⁹R¹⁰ or (NR⁹R¹⁰)alkyl;

R⁸ is

10 (i) alkyl, alkenyl, heterocyclo, (heterocyclo)alkyl, (hydroxy)alkyl, (alkoxy)alkyl, (aryloxy)alkyl, heteroaryl, aryl or (aryl)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T⁷, T⁸ and/or T⁹; or

(ii) -NR⁹R¹⁰ or (NR⁹R¹⁰)alkyl;

15 R⁹ and R¹⁰ are independently H, alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or (heterocyclo)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T⁷, T⁸ and/or T⁹;

20 T¹-T⁹ are each independently

25 (i) alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently substituted by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, -OT¹⁰, -SH, -ST¹⁰, -C(O)_tH, -C(O)_tT¹⁰, -O-C(O)T¹⁰, T¹⁷C(O)_tN(T¹¹)T¹⁰, -SO₃H, -S(O)_tT¹⁰, S(O)_tN(T¹¹)T¹⁰, -T¹²-NT¹⁴T¹⁵, -T¹²-N(T¹¹)-T¹³-NT¹⁴T¹⁵, -T¹²-N(T¹⁶)-T¹⁵-T¹⁰ and -T¹²-N(T¹⁶)-T¹³-H; or

30 (ii) halo, cyano, nitro, OH, oxo, -SH, amino, -OT¹⁰, -ST¹⁰, -C(O)_tH, -C(O)_tT¹⁰, -O-C(O)T¹⁰, T¹⁷C(O)_tN(T¹¹)T¹⁰, -SO₃H, -S(O)_tT¹⁰, S(O)_tN(T¹¹)T¹⁰, -T¹²-NT¹⁴T¹⁵, -T¹²-N(T¹¹)-T¹³-NT¹⁴T¹⁵, -T¹²-N(T¹⁶)-T¹⁵-T¹⁰ or -T¹²-N(T¹⁶)-T¹³-H;

t is 1 or 2;

T^{10} is alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl;

5 T^{12} and T^{13} are each independently a single bond, $-T^{17}-S(O)_t-T^{18}-$, $-T^{17}-C(O)-T^{18}-$, $-T^{17}-C(S)-T^{18}-$, $-T^{17}-O-T^{18}-$, $-T^{17}-S-T^{18}-$, $-T^{17}-O-C(O)-T^{18}-$, $-T^{17}-C(O)_t-T^{18}-$, $-T^{17}-C(=NT^{19})-T^{18}-$ or $-T^{17}-C(O)-C(O)-T^{18}-$;

T^{11} , T^{14} , T^{15} , T^{16} and T^{19} are each independently


- (i) hydrogen, alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently substituted where valence permits by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl, (heteroaryl)alkyl, $-SH$, $-ST^{22}$, $-C(O)_tH$, $-C(O)_tT^{22}$, $-O-C(O)T^{22}$ and $-S(O)_tT^{22}$; or
- (ii) halo, cyano, nitro, OH, oxo, $-SH$, amino, $-OT^{22}$, $-ST^{22}$, $-C(O)_tH$, $-C(O)_tT^{22}$, $-O-C(O)T^{22}$, $-SO_3H$, $-S(O)_tT^{22}$ or $S(O)_tN(T^{11})T^{22}$;
- (iii) T^{14} and T^{15} may together be alkylene or alkenylene, completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is substituted with one or more groups listed in the description of T^{20} ; or
- (iv) T^{14} or T^{15} , together with T^{11} , may be alkylene or alkenylene completing a 3- to 8-membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is substituted with one or more groups listed in the description of T^{20} ; or
- (v) T^{14} and T^{15} or T^{11} and T^{16} together with the nitrogen atom to which they are attached may combine to form a group $-N=CT^{20}T^{21}$;


30 T^{17} and T^{18} are each independently a single bond, alkylene, alkenylene or alkynylene; T^{20} and T^{21} are each

(i) independently hydrogen, alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently substituted where valence permits by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl, (heteroaryl)alkyl, —SH, —ST²², —C(O)_tH, —C(O)_tT²², —O-C(O)T²² and —S(O)_tT²²; or


(ii) halo, cyano, nitro, OH, oxo, —SH, amino, —OT²², —ST²², —C(O)_tH, —C(O)_tT²², —O-C(O)T²², —SO₃H, —S(O)_tT²² or S(O)_tN(T¹¹)T²²; and T²² is alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl.


More preferred compounds are compounds within the scope Formula (Ia), their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, in which Z is selected from





Also more preferred compounds include compounds within the scope of Formula (Ia), their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, in which R⁵ is selected from:






5

10

Preferred compounds within the scope of the present invention include compounds having Formula (II)

15




(II)

their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, in which:

Q is O, S or optionally substituted C₁ alkylene (more preferably Q is -CH₂- or O); and
5 X¹, X², X³ and X⁴ are

- (i) independently chosen from hydrogen, T¹⁰, OT¹⁰ and NT¹⁴T¹⁵; and/or
- (ii) either X¹ and X² or X³ and X⁴ may be taken together to be a carbonyl group.

10 Preferred compounds within the scope of the present invention include compounds having Formula (III)



(III)

15 their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, in which:

X¹, X², X³ and X⁴ are

- (i) independently chosen from hydrogen, T¹⁰, OT¹⁰ or NT¹⁴T¹⁵; and/or
- (ii) either X¹ and X² or X³ and X⁴ may be taken together to be a carbonyl group.

20


More preferred compounds are compounds within the scope of Formula (III) (above), their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, in which X¹, X², X³ and X⁴ are independently chosen from hydrogen, T¹⁰, OT¹⁰ or NT¹⁴T¹⁵.

25

More preferred compounds also include compounds within the scope of Formula (III), their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, in which:

X^1 , X^2 are independently chosen from hydrogen, T^{10} , OT^{10} or $NT^{14}T^{15}$; and X^3 and X^4 are taken together to be a carbonyl group.

Preferred compounds within the scope of the present invention include
5 compounds having Formula (IV)




(IV)

their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and
10 solvates thereof, wherein:

Q is O, S or optionally substituted C_1 alkylene (more preferably Q is $-CH_2-$ or O), and
 X^1 , X^2 , X^3 , X^4 , X^5 and X^6 are

- (i) independently chosen from hydrogen, T^{10} , OT^{10} or $NT^{14}T^{15}$; and/or
- (ii) any one of X^1 and X^2 or X^3 and X^4 or X^5 and X^6 may be taken
15 together to be a carbonyl group.

More preferred compounds of the present invention include compounds of
Formulas (I), (II), (III), or (IV), their enantiomers, diastereomers, and
pharmaceutically acceptable salts, prodrugs and solvates thereof, in which R^2 is
20 chosen from :



W is O or S;


Y¹ is -NHT¹⁵ or OT¹⁰;

Y² and Y³ are independently hydrogen, halo, OT¹⁰, alkyl or haloalkyl;

5 Y⁴ is optionally substituted heteroaryl, cyano, C(O)_tT¹⁰ or S(O)_tNT¹⁴T¹⁵; and

Y⁵ is alkyl, haloalkyl, NHT¹⁵ or OT¹⁰.

Even more preferred compounds of the present invention include compounds of Formulas (I), (Ia), (II), (III), or (IV), their enantiomers, diastereomers, and 10 pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R² is



W is O or S (preferably S);

15 Y¹ is -NHT¹⁵ or OT¹⁰ (preferably OT¹⁰) and

Y² is alkyl, or haloalkyl (preferably alkyl).

More preferred compounds of the present invention include compounds of Formulas (I), (Ia), (II), (III), or (IV), their enantiomers, diastereomers, and 20 pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R¹ is H;

J¹ is O, S or optionally substituted C₁ alkylene;

J² is C(O), or optionally substituted C₁₋₃ alkylene.;

Z is -NR³R⁴ or halo;

25 R³ is H or alkyl;

Even more preferred compounds of the present invention include compounds of Formula (I), (Ia), (II), (III), or (IV) include:

i. 2-[7-(4-Methanesulfonyl-benzyl)-4-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

30

2-[7-(4-Methanesulfonyl-benzyl)-4-methylamino-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]- 4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[7-(3,4-Dimethoxy-benzyl)-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-
5 pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-(2-Cyclohex-1-enyl-ethylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-
pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

10 2-[4-(Butoxycarbonylmethyl-amino)-7-pyridin-3-ylmethyl-5,6-dihydro-
pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-(4-Cyclopentylamino-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino)-4-methyl-thiazole-5-carboxylic acid ethyl ester;

15 4-Methyl-2-{4-[(5-methyl-furan-2-ylmethyl)-amino]-7-pyridin-3-ylmethyl-
5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino }-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-{4-[3-(2-methyl-piperidin-1-yl)-propylamino]-7-pyridin-3-
20 ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino }-thiazole-5-
carboxylic acid ethyl ester;

4-Methyl-2-[4-(2-oxo-azepan-3-ylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-
pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-{7-pyridin-3-ylmethyl-4-[(thiophen-2-ylmethyl)-amino]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester;

2-[4-(3-Imidazol-1-yl-propylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-[4-(1-carboxyethyl-piperidin-4-ylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

2-[4-(6-Dimethylamino-hexylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-[4-(2-pyridin-4-yl-ethylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

2-[4-(4-Hydroxy-butylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-{4-[(1-Ethyl-pyrrolidin-2-ylmethyl)-amino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-(2-Acetylamino-ethylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-{4-[2-(1-methyl-pyrrolidin-2-yl)-ethylamino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester;

2-[4-(1-Hydroxymethyl-butylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-[4-(3-morpholin-4-yl-propylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

2-{4-[2-(1H-Imidazol-4-yl)-ethylamino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-{(S)-2-Carbamoyl-pyrrolidin-1-yl}-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-(3-Hydroxy-pyrrolidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-(4-morpholin-4-yl-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino)-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-{4-[methyl-(1-methyl-piperidin-4-yl)-amino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester;

2-[4-(3-Diethylcarbamoyl-piperidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-{4-[4-(2-Hydroxy-ethyl)-piperidin-1-yl]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-{4-[4-(2-oxo-2-pyrrolidin-1-yl-ethyl)-piperazin-1-yl]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester;

2-{4-[4-(Furan-2-carbonyl)-piperazin-1-yl]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester,

2-[4-(4-Hydroxy-piperidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-(3-Acetylamino-pyrrolidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-{4-[Ethyl-(1-ethyl-pyrrolidin-3-yl)-amino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-[4-(4-carboxyethyl-piperidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

2-[4-(4-Acetyl-piperazin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-{4-[3-(2-oxo-pyrrolidin-1-yl)-propylamino]-7-[4-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-(4-morpholin-4-yl-6-oxo-7-pyridin-4-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino)-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-[4-morpholin-4-yl-8-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-[4-methylamino-8-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

2-[8-(4-Ethanesulfonylamino-benzyl)-4-(3-oxo-piperazin-1-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-(2-Acetylamino-ethylamino)-8-(4-ethanesulfonylamino-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[8-(4-Methanesulfonylaminocarbonyl-benzyl)-4-(3-oxo-piperazin-1-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-(4-Hydroxy-piperidin-1-yl)-9-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester; or

2-[4-(4-Acetyl-[1,4]diazepan-1-yl)-9-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester; or

ii. the enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates of each of (i).

10

Methods of Preparation

Compounds having the structure of Formula (I) may be prepared by reference to the methods illustrated in the following Schemes A through D. In particular, Schemes A1, A2, A3 and A4 depict various methods by which compounds of Formula (I) may be prepared. Scheme B illustrates the preparation of key intermediate 2-substituted malonates. Scheme C depicts a method by which amides of Formula (I) may be prepared from esters of Formula (I). Finally, schemes D1 and D2 outline the preparation of the intermediate guanidines.


One of skill in the art understands that any compound of Formula (I) may be produced by the above Schemes by the suitable selection of appropriate substitution. Solvents, temperatures, pressures, and other reaction conditions may readily be selected by one of ordinary skill in the art. All documents cited are incorporated herein by reference in their entirety. Starting materials are commercially available or readily prepared by one of ordinary skill in the art. Constituents of compounds are as defined herein or elsewhere in the specification.

Compounds within the scope of the present invention may be prepared by several methods. Compounds of formula II, III, or IV where Q is not a heteroatom is prepared as shown in Scheme A1. Guanidine A1.1 is heated in the presence of a base such as sodium ethoxide with an appropriate 2-substituted malonate A1.2 to produce intermediate A1.3 which upon reaction with phosphorous oxychloride at elevated temperature provides intermediate A1.4. Cleavage of the olefin by a two step

protocol involving dihydroxylation with osmium tetroxide in the presence of a co-oxidant such as N-methylmorpholine N-oxide to give intermediate A1.5 followed by reaction with either sodium periodate or lead(IV) acetate to provide intermediate A1.6. Reductive amination of A1.6 using sodium triacetoxyborohydride and acetic acid in THF with amine A1.7 results in spontaneous ring closure giving intermediate A1.8. Reaction with reagent A1.9, (an alcohol, a thiol or a sulfonamide) in the presence of a suitable base provides A1.10 which is a compound described by Formula II, III, or IV.

Scheme A1


10



In the case of compounds of Formula II, III, or IV where Q is a heteroatom (Scheme A2), guanidine A1.1 is heated in the presence of a base such as sodium ethoxide with an appropriate 2-substituted malonate A2.1 to produce intermediate A2.2. Reaction of A2.2 with phosphorous oxychloride in the presence of a base at elevated temperature provides intermediate A2.3. Heating with amine A1.7 in the

presence of a base such as triethylamine or Hunigs base in a solvent such as N-methyl pyrrolidone followed by hydrolysis with aqueous acid provides intermediate A2.4. A2.4 is then reduced with sodium cyanoborohydride in acetic acid to A2.5. Reaction with reagent A1.9, (an amine, alcohol, thiol or sulfonamide) in the presence of a suitable base provides compound A2.6 which is a compound of Formula II, III, or IV.


Scheme A2



10 For the preparation of lactams of Formula II, III, or IV where Q is not a heteroatom (Scheme A3), guanidine A1.1 is heated in the presence of a base such as sodium ethoxide with an appropriate 2-substituted malonate A3.1 to produce intermediate A3.2. Reaction of A3.2 with phosphorous oxychloride at elevated temperature provides intermediate A3.3 which is then heated with amine A1.7 in the presence of a base such as triethylamine or Hunigs base in a solvent such as N-methyl pyrrolidone. Reagent A1.9 (an amine, alcohol, thiol or sulfonamide) is then added

directly to the “same pot” and heated to provide compound A3.3 which is described by Formula II, III, or IV.


Scheme A3




5

Alternatively, lactams of Formula II or IV where Q is a heteroatom (Scheme A4), can be prepared directly from intermediate A2.4 by reaction with an oxidant such as pyridinium dichromate (see Takano, *et al.*, *J. Chem. Soc.*, 2, 156-158 (1986)), manganese dioxide (see Nakatsuka *et al.*, *Tetrahedron Lett.*, 28, 3671-3674 (1987)) or Jones reagent (see Morales-Rios, *et al.*, *Tetrahedron*, 52, 5339-5348 (1996)) to provide intermediate A4.1. Reaction with reagent A1.9, (an amine, alcohol, thiol or sulfonamide) in the presence of a suitable base provides compound A4.2.

15

Scheme A4


2-Substituted malonates, A1.2, A2.1, and A3.1, are either commercially available, or readily prepared by one of the methods outlined in Scheme B (entries 1-3). As depicted in Scheme B (entry 1), malonate esters, B1, can be alkylated at the 2-position with alkyl halides using bases such as sodium hydride or sodium alkoxide in solvents (including DMF or THF) to afford intermediates, B3. See e.g., Molander, *et al.*, *J. Am. Chem. Soc.*, 118, 4059-4071 (1996). As shown in Scheme B, (entry 2), 2-halo-malonate esters, B4, undergo displacement with nucleophiles including thiolates generated from the respective thiols by deprotonation with bases such as sodium ethoxide. See e.g., Aveta, *et al.*, *Gazz. Chim. Ital.*, 116, 649-652 (1996). It is well documented in the literature that sulfides such as intermediate B6 can be selectively oxidized either to the sulfoxide, B7, or sulfone, B8, with oxidants (including *m*-chloroperoxybenzoic acid) by careful regulation of experimental conditions such as temperature. See e.g., Fujisawa, *et al.*, *Tetrahedron Lett.*, 25, 5083-5086 (1984); and Sutton, *et al.*, *Org. Lett.*, 2, 319-322 (2000). Additionally, as depicted in Scheme B (entry 3), 2-substituted malonates, B10, can be prepared by the reaction of diazomalonates with alcohols at elevated temperatures in solvents such as benzene, chloroform or toluene in the presence of transition metal catalysts, such as $\text{Rh}(\text{OAc})_2$ dimer. See e.g., Connell, *et al.*, *Tetrahedron*, 49, 5445-5460 (1993).

Scheme B


Scheme C outlines the conversion of esters of Formula (I) to amides of

5 Formula (I). Hydrolysis of the ester C1.1 under basic conditions (using e.g., sodium hydroxide) affords acid C2. Alternatively, one may use a protecting group (such as a *tert*-butyl or benzyl group as depicted in compounds C1.2 and C2.3, respectively) which will readily allow removal (for instance, by treatment with trifluoroacetic acid or reaction with hydrogen in the presence of a suitable catalyst such as palladium on carbon under elevated pressure) to produce acid C2. See e.g., Greene, Theodora W., *et al.*, Protective Groups in Organic Synthesis, 3rd ed. Coupling of acid C2 via standard amide bond coupling techniques (EDCI/HOAt) with the appropriate amine, C3, gives the desired amide, C4.

10

Scheme C

The appropriately substituted guanidines referred to in scheme A are either commercially available or readily prepared by a number of methods known to one skilled in the art of organic chemistry. As depicted in scheme D1, amines D1.1 may be reacted with a number of reagents, such as the commercially available 2,3,5-dimethylpyrazole-1-carboxamidine nitrate, D1.2, to provide the desired guanidine, D1.3.

Scheme D1


10

In some instances it is more convenient to prepare the intermediate guanidines as illustrated in Scheme D2. An *alpha*-haloketone, D2.1, is reacted with 2-imino-4-thiobiuret, D2.2, to provide guanidine salt D2.3, which is liberated by

treatment with a basic resin, or sodium hydroxide, sodium methoxide, or an amine base to provide intermediate D2.4. Then, D2.4 can be further elaborated as described in Scheme A to provide compounds of Formula (I).

Scheme D2

5



10

Utility

The compounds of Formula (I), are useful in the treatment (including prevention, partial alleviation or cure) of leukocyte activation-associated disorders. These disorders include (but are not limited to) transplant rejection (such as organ transplant, acute transplant, xenotransplant or heterograft or homograft such as is employed in burn treatment); protection from ischemic or reperfusion injury such as ischemic or reperfusion injury incurred during organ transplantation, myocardial infarction, stroke or other causes; transplantation tolerance induction; arthritis (such as rheumatoid arthritis, psoriatic arthritis or osteoarthritis); multiple sclerosis; respiratory and pulmonary diseases including but not limited to asthma, exercise induced asthma, chronic obstructive pulmonary disease (COPD), emphysema, bronchitis, and acute respiratory distress syndrome (ARDS); inflammatory bowel disease, including ulcerative colitis and Crohn's disease; lupus (systemic lupus erythematosus); graft vs. host disease; T-cell-mediated hypersensitivity diseases, including contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy (Celiac disease); psoriasis; contact dermatitis (including that due to poison ivy); Hashimoto's thyroiditis; Sjogren's syndrome; Autoimmune

Hyperthyroidism, such as Graves' Disease; Addison's disease (autoimmune disease of the adrenal glands); Autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome); autoimmune alopecia; pernicious anemia; vitiligo; autoimmune hypopituitarism; Guillain-Barre syndrome; other autoimmune diseases; 5 glomerulonephritis; serum sickness; urticaria; allergic diseases such as respiratory allergies (e.g., asthma, hayfever, allergic rhinitis) or skin allergies; scleroderma; mycosis fungoides; acute inflammatory and respiratory responses (such as acute respiratory distress syndrome and ischemia/reperfusion injury); dermatomyositis; alopecia areata; chronic actinic dermatitis; eczema; Behcet's disease; Pustulosis 10 palmoplantar; Pyoderma gangrenum; Sezary's syndrome; atopic dermatitis; systemic sclerosis; and morphea.

15 The term "leukocyte activation-associated disorder" or "leukocyte activation-mediated disorder" as used herein includes each of the above referenced diseases or disorders. The compounds of the present invention are useful for treating the aforementioned exemplary disorders irrespective of their etiology.

20 The present invention thus provides methods for the treatment of leukocyte activation-associated disorders (discussed above) comprising the step of administering to a subject in need thereof of at least one compounds of Formula (I). Other therapeutic agents such as those described below may be employed with the compounds of the present invention. In the methods of the present invention, such other therapeutic agent(s) may be administered prior to, simultaneously with or following the administration of the compound(s) of the present invention.

25 The methods of treating diseases which would benefit from administering compounds of Formula (I) alone or in combination with each other and/or other suitable therapeutic agents useful in treating such conditions. These agents include, without limitation: immunosuppressants such as cyclosporins (e.g., cyclosporin A), anti-IL-1 agents, such as Anakinra®, the IL-1 receptor antagonist, CTLA4-Ig, antibodies such as anti-ICAM-3, anti-IL-2 receptor (Anti-Tac®), anti-CD45RB, anti-CD2, anti-CD3, anti-CD4, anti-CD80, anti-CD86, monoclonal antibody OKT3, agents 30 blocking the interaction between CD40 and CD154, such as antibodies specific for CD40 and/or CD154 (i.e., CD40L), fusion proteins constructed from CD40 and CD154 (CD40Ig and CD8-CD154), interferon beta, interferon gamma, methotrexate,

FK506 (tacrolimus, Prograf®), rapamycin (sirolimus or Rapamune®)mycophenolate mofetil, leflunomide (Arava®), azathioprine and cyclophosphamide, inhibitors, such as nuclear translocation inhibitors, of NF-kappa B function, such as deoxyspergualin (DSG), non-steroidal antiinflammatory drugs (NSAIDs) such as ibuprofen, 5 cyclooxygenase-2 (COX-2) inhibitors such as celecoxib (Celebrex®) and rofecoxib (Vioxx®), or derivatives thereof, steroids such as prednisone or dexamethasone, gold compounds TNF- α inhibitors such as tenidap, anti-TNF antibodies or soluble TNF receptor such as etanercept (Enbrel®), inhibitors of p-38 kinase such as BIRB-796, RO-3201195, VX-850, and VX-750, *beta*-2 agonists such as albuterol, levalbuterol 10 (Xopenex®), and salmeterol (Serevent®), inhibitors of leukotriene synthesis such as montelukast (Singulair®) and zariflukast (Accolate®), and anticholinergic agents such as ipratropium bromide (Atrovent®), PDE4 inhibitors such as Arofylline, Cilomilast, Roflumilast, C-11294A, CDC-801, BAY-19-8004, Cipamfylline, 15 SCH351591, YM-976, PD-189659, Mesiopram, Pumafentri, CDC-998, IC-485, and KW-4490, and PDE7 inhibitors such as IC242. *See* Lee, *et al.*, *Cell Signalling*, 14, 277-284, (2002). Other compounds which may be used in combination with 20 compounds of Formula (I) to treat diseases are disclosed in the following patent documents: WO 0068230, WO 0129049, WO 0132618, WO 0134601, WO 0136425, WO 0174786, WO 0198274, WO 0228847; U.S. Prov. Appl. Serial Nos. 60/287,964, 25 and 60/355,141; as well as anti-cytokines such as anti-IL-1 mAb or IL-1 receptor agonist; anti-IL-4 or IL-4 receptor fusion proteins; and PTK inhibitors such as those disclosed in U.S Patent Nos. 5,990,109, 6,235,740 and 6,239,133, U.S. Appl. Ser. Nos. 60/065,042 and. 09/173,413, filed 11/10/97 and 10/15/98, respectively. All of the foregoing patents and patent applications are incorporated herein by reference in their entirety.

See also the following documents and references cited therein:

Hollenbaugh, D., *et al.*, *J. Immunol. Methods*, 188(1), 1-7 (1995); Hollenbaugh, D., *et al.*, *EMBO J.*, 11(12),4313-4321 (1992); and Moreland, L.W., *et al.*, *New England J. of Medicine*, 337(3), 141-147 (1997).

30 The above other therapeutic agents, when employed in combination with the compounds of the present invention, may be used, for example, in those amounts

indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.

Use of the compounds having Formula (I) of the present invention in treating leukocyte activation-associated disorders is exemplified by, but is not limited to, treating a range of disorders such as: transplant (such as organ transplant, acute transplant, xenotransplant or heterograft or homograft (such as is employed in burn treatment)) rejection; protection from ischemic or reperfusion injury such as ischemic or reperfusion injury incurred during organ transplantation, myocardial infarction, stroke or other causes; transplantation tolerance induction; arthritis (such as 5 rheumatoid arthritis, psoriatic arthritis or osteoarthritis); multiple sclerosis; respiratory and pulmonary diseases including but not limited to asthma, exercise induced asthma, chronic obstructive pulmonary disease (COPD), emphysema, bronchitis, and acute respiratory distress syndrome (ARDS); inflammatory bowel disease, including 10 ulcerative colitis and Crohn's disease; lupus (systemic lupus erythematosis); graft vs. host disease; T-cell mediated hypersensitivity diseases, including contact 15 hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy (Celiac disease); psoriasis; contact dermatitis (including that due to poison ivy); Hashimoto's thyroiditis; Sjogren's syndrome; Autoimmune Hyperthyroidism, such as 20 Graves' Disease; Addison's disease (autoimmune disease of the adrenal glands); Autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome); autoimmune alopecia; pernicious anemia; vitiligo; autoimmune 25 hypopituitarism; Guillain-Barre syndrome; other autoimmune diseases; glomerulonephritis; serum sickness; urticaria; allergic diseases such as respiratory allergies (asthma, hayfever, allergic rhinitis) or skin allergies; scleroderma; mycosis fungoides; acute inflammatory and respiratory responses (such as acute respiratory distress syndrome and ischémia/reperfusion injury); dermatomyositis; alopecia areata; chronic actinic dermatitis; eczema; Behcet's disease; Pustulosis 30 palmoplantaris; Pyoderma gangrenum; Sezary's syndrome; atopic dermatitis; systemic sclerosis; and morphea.

The combined activity of the present compounds towards T-cells may be of value in the treatment of any of the aforementioned disorders.

In a particular embodiment, the compounds of the present invention are useful for the treatment of the aforementioned exemplary disorders irrespective of their etiology, for example, in the treatment of transplant rejection, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease, inflammatory bowel disease, lupus, graft v. host disease, T-cell mediated hypersensitivity disease, psoriasis, Hashimoto's thyroiditis, Guillain-Barre syndrome, cancer, contact dermatitis, allergic disease such as allergic rhinitis, asthma, ischemic or reperfusion injury, respiratory diseases such as asthma, COPD and bronchitis or atopic dermatitis.

10 *T-cell Proliferation Assay*

Peripheral blood mononuclear cells (PBMC) were isolated from whole blood by density gradient centrifugation over Lymphoprep, 1.077. Cells were plated into 96 well U-bottom plates at 2.5×10^5 cells/well in 10% FBS RPMI 1640 (Life Technologies/Gibco-BRL) containing 10ug/ml anti-CD3 (G19-4, Bristol-Myers Squibb P.R.I., Princeton, NJ) and 1ug/ml anti-CD28 (9.3, Bristol-Myers Squibb P.R.I.) in the presence and absence of inhibitors. DMSO (used as a solvent for inhibitors) was added to the medium at 0.1% final concentration. The total volume per well was 200 μ L. Cells were incubated at 37C 5% CO₂ for 3 days, at which time 0.5 μ Ci of ³H-thymidine was added to each well. Six hours following the addition of ³H-thymidine, the plates were harvested onto filter plates, 30ul EcoLite scintillant (ICN, Costa Mesa, CA) was added per well, and plates read on a Top Count-NXT scintillation counter.

25 *TNF α secretion assay*

The ability of compounds to inhibit the production and secretion of TNF α from leukocytes was performed using either PBMC (obtained as described above) or the THP-1 cell line as a source of monocytes. Compounds were diluted in RPMI 1640 supplemented with 10% FBS and DMSO at a final concentration of 0.2%. Cells (2×10^5 /well in U-bottom 96 well plates) were pre-incubated with compounds for 30 min at 37 C prior to addition of lipopolysaccharide (LPS) at a final concentration of 6.25 ng/ml in a total volume of 200 μ L. After 4h at 37 °C, 50 μ L of supernatant was carefully aspirated for detection of soluble TNF α . Soluble TNF α was detected by

ELISA developed by R&D Systems (Minneapolis, MN) according to the manufacturer's instructions.

Examples

The following examples illustrate preferred embodiments of the present invention and do not limit the scope of the present invention which is defined in the 5 claims. Abbreviations employed in the Examples are defined below. Compounds of the Examples are identified by the example and step in which they are prepared (e.g., “A1.1” denotes the title compound of step 1 of Example A1), or by the example only where the compound is the title compound of the example (for example, “A2” denotes the title compound of Example A2).

10 Abbreviations


Ac	Acetyl	
AcOH	Acetic acid	
aq.	Aqueous	
CDI	Carbonyldiimidazole	
15	Bn	Benzyl
	Bu	Butyl
	Boc	tert-butoxycarbonyl
	DMAP	Dimethylaminopyridine
	DMA	N,N-Dimethylacetamide
20	DMF	dimethylformamide
	DMSO	Dimethylsulfoxide
	EDC	1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
	EtOAc	Ethyl acetate
	Et	Ethyl
25	EtOH	Ethanol
	H	Hydrogen
	h	Hours
	<i>i</i>	<i>iso</i>
	HPLC	High pressure liquid chromatography
30	HOAc	Acetic acid
	Lawesson's Reagent	[2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2-4-disulfide
	LC	liquid chromatography

	Me	Methyl
	MeOH	Methanol
	min.	Minutes
	M ⁺	(M+H) ⁺
5	M ⁺¹	(M+H) ⁺
	MS	Mass spectrometry
	<i>n</i>	<i>normal</i>
	Pd/C	Palladium on carbon
	Ph	Phenyl
10	Pr	Propyl
	Ret Time	Retention time
	rt or RT	Room temperature
	sat.	Saturated
	S-Tol-BINAP	(S)-(-)-2,2'-Bis(di-p-tolylphosphino)-1,1'-binaphthyl
15	<i>t</i>	<i>tert</i>
	TFA	Trifluoroacetic acid
	THF	Tetrahydrofuran
	YMC	YMC Inc, Wilmington, NC 28403

20


Example A1

2-[4-(4-Hydroxy-piperidin-1-yl)-7-pyridin-2-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester



A1.1: 2-[(Aminoiminomethyl)amino]-4-methyl-5-thiazolecarboxylic acid ethyl ester


25



A1.1


A solution of 2-imino-4-thiobiuret (20.0g, 0.17 mol), 2-chloroacetoacetate (28g, 0.17 mol) in ethanol (500 mL) was heated to 100°C for 4 hours. The reaction mixture was concentrated to half volume and poured into 1 liter of 1N NaOH. The 5 white solid which precipitated out was collected by filtration and dried under vacuum to yield **A1.1** (30.5g, 79%). $^1\text{H-NMR}$ (DMSO-d₆) δ : 4.22 (2H, q, J = 7 Hz), 2.50 (3H, merge with DMSO), 1.26 (3H, t, J = 7 Hz). HPLC: 97.7%, ret. time = 1.619 min., LC/MS (M+H)⁺ = 229.

10 **A1.2:** 2-(5-Allyl-4,6-dioxo-1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-4-methyl-thiazole-5-carboxylic acid ethyl ester

**A1.2**

15 To a solution of NaOEt in EtOH [prepared by dissolving Na (88 mg, 3.83 mmol, 2.5 eq) in 15 mL of absolute ethanol] was added **A1.1** (350 mg, 1.53 mmol, 1 eq) and the mixture was stirred at rt for 20 min. Diethyl allylmalonate (0.30 mL, 1.53 mmol, 1 eq) was added dropwise, the reaction mixture was heated at reflux for 22 h and then cooled and poured onto a mixture of ice and 10% aq H₂SO₄. The solid was 20 collected by filtration, washed with water and dried to afford **A1.2** (346 mg, 67% yield) as a tan solid. LC/MS: 337.58 [M+H]⁺; HPLC: 93 % at 3.49 min (Phenomenex Luna 5 μm C18 column 4.6 x 50 mm, 10-90 % aqueous methanol over 4 min containing 0.2% phosphoric acid, 4 mL/min, monitoring at 220 nm).

A1.3: 2-(5-Allyl-4,6-dichloro-pyrimidin-2-ylamino)-4-methyl-thiazole-5-carboxylic acid ethyl ester




5

A1.3

A mixture of **A1.2** (346 mg, 1.03 mmol, 1 eq) and POCl_3 (5 mL) was heated in a 100 °C oil bath for 19 h. The reaction mixture was poured onto ice, neutralized with 2 N NaOH, and extracted with ethyl acetate. The organic phase was washed with sat. NaHCO_3 , water and brine, dried over MgSO_4 and concentrated to afford **A1.3** (285 mg, 74% yield) as a yellow solid. LC/MS: 337.58 $[\text{M}+\text{H}]^+$; HPLC: >95 % at 2.10 min (Xterra 5 μm C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% phosphoric acid, 5 mL/min, monitoring at 254 nm). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 5.90 (m, 1 H), 5.10 (m, 2 H), 4.27 (q, $J = 7.1$ Hz, 2 H), 3.53 (m, 2 H), 2.55 (s, 3H), 1.29 (t, $J = 7.1$ Hz, 3 H).

15

A1.4: 2-[4,6-Dichloro-5-(2-oxo-ethyl)-pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester




20

A1.4

A solution of **A1.3** (109 mg, 0.292 mmol, 1 eq) and NMO monohydrate (79 mg, 0.584 mmol, 2 eq) in $\text{THF}/\text{H}_2\text{O}$ (6:1, 6.4 mL) was cooled to 0 °C and a 4 wt % aq solution of OsO_4 (0.18 mL, 0.029 mmol, 0.1 eq) was added. The reaction mixture was warmed to rt, stirred for 41 h and then quenched with a solution of 80 mg of NaHSO_3 in 5 mL H_2O and extracted twice with ethyl acetate. The organic phase was washed with water and brine, dried over Na_2SO_4 and concentrated.

The crude product in THF/ethanol/water (4:1:2, 5 mL) was cooled to 0 °C, NaIO₄ (125 mg, 0.584 mmol, 2 eq) was added portionwise and the reaction mixture was stirred at 0 °C for 3h and then warmed to rt and stirred overnight. The mixture was poured into water and extracted with ethyl acetate. The organic layer was 5 washed with brine, dried over Na₂SO₄ and concentrated. The crude product was passed through a silica gel plug eluted first with dichloromethane (discarded) and then with ethyl acetate. The ethyl acetate fractions were concentrated to afford **A1.4** (85 mg, 78% yield) as a white solid. HPLC: >95 % at 3.58 min (Phenomenex Luna 5 µm 10 C18 column 4.6 x 50 mm, 10-90 % aqueous methanol over 4 min containing 0.2% phosphoric acid, 4 mL/min, monitoring at 254 nm). ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.72 (s, 1 H), 4.27 (q, *J* = 7.1 Hz, 2 H), 4.11 (m, 2 H), 2.56 (s, 3H), 1.29 (t, *J* = 7.1 Hz, 3 H).

15 **A1.5: 2-(4-Chloro-7-pyridin-2-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino)-4-methyl-thiazole-5-carboxylic acid ethyl ester**



A1.5


A mixture of **A1.4** (34 mg, 0.0911 mmol, 1 eq) in THF (1 mL) was treated 20 with 2-picolyamine (10.3 mg, 0.0957 mmol, 1.05 eq), Na(OAc)₃BH (29 mg, 0.137 mmol, 1.5 eq) and acetic acid (5.2 µL, 0.0911 mmol, 1 eq). The reaction mixture was stirred at rt for 10 min, 3 drops of Et₃N were added and stirring continued for 1 h. The mixture was poured into sat. NaHCO₃, extracted twice with ethyl acetate and the combined organic layers were washed with brine, dried over Na₂SO₄ and 25 concentrated. Column chromatography (SiO₂, eluted with ethyl acetate) gave **A1.5** (25 mg, 64% yield) as an off-white solid. LC/MS: 431.46 [M+H]⁺; HPLC: >95 % at 3.20 min (Phenomenex Luna 5 µm C18 column 4.6 x 50 mm, 10-90 % aqueous methanol over 4 min containing 0.2% phosphoric acid, 4 mL/min, monitoring at 254

nm). ^1H NMR (400 MHz, CDCl_3): δ 9.53 (brs, 1 H), 8.58 (d, J = 4.9 Hz, 1 H), 7.67 (ddd, J = 1.7, 7.7, 7.7 Hz, 1 H), 7.37 (d, J = 7.7 Hz, 1 H), 7.22 (m, 1H), 4.79 (s, 2 H), 4.28 (q, J = 7.1 Hz, 2 H), 3.77 (t, J = 8.4 Hz, 2 H), 3.03 (J = 8.2 Hz, 2 H), 2.65 (s, 3H), 1.30 (t, J = 7.1 Hz, 3 H).

5

A1.6: 2-[4-(4-Hydroxy-piperidin-1-yl)-7-pyridin-2-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester

A mixture of **A1.5** (15 mg, 0.0348 mmol, 1 eq), 4-hydroxypiperidine (7 mg, 0.0696 mmol, 2 eq), Hunig's base (18 μL , 0.1044 mmol, 3 eq) and n-butanol (0.5 mL) 10 was heated in a sealed tube at 150 °C until the reaction was complete by HPLC analysis. The reaction mixture was cooled to rt and concentrated in vacuo. Column chromatography (SiO_2 , 5% methanol/ethyl acetate) provided **A1** (10.4 mg, 60% yield) as an oil. LC/MS: 496.57 $[\text{M}+\text{H}]^+$; HPLC: 95 % at 1.22 min (Xterra 5 μm C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% 15 phosphoric acid, 5 mL/min, monitoring at 254 nm). ^1H NMR (400 MHz, CDCl_3): δ 8.70 (brs, 1 H), 8.55 (d, J = 4.7 Hz, 1 H), 7.63 (ddd, J = 1.7, 7.7, 7.7 Hz, 1 H), 7.33 (d, J = 7.8 Hz, 1 H), 7.18 (m, 1H), 4.69 (s, 2 H), 4.26 (q, J = 7.1 Hz, 2 H), 4.15-4.20 (m, 2 H), 3.94 (m, 1 H), 3.53 (t, J = 8.4 Hz, 2 H), 3.28 (m, 2 H), 3.09 (J = 8.4 Hz, 2 H), 2.60 (s, 3H), 1.96 (m, 2 H), 1.58 (m, 2 H), 1.31 (t, J = 7.1 Hz, 3 H).









Example A2-A72











Examples A2 to A72 were prepared from intermediate A1.4 in a similar manner to that used for Example A1 utilizing the appropriate amine replacements.

Table A

Ex.	Z	R ⁵	Name	HPLC Retention (min)	MS Reported
A2			2-[7-(4-Methanesulfonylbenzyl)-4-piperazin-1-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.19 ^a	558.44
A3			4-Methyl-2-[4-piperazin-1-yl-7-(3,4,5-trimethoxybenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.35 ^a	570.24
A4			4-Methyl-2-[4-(4-methyl-piperazin-1-yl)-7-(3,4,5-trimethoxybenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.34 ^a	584.56

A5			4-Methyl-2-[4-(3-oxo-piperazin-1-yl)-7-pyridin-2-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.18 ^a	495.51
A6			2-[7-(4-Methanesulfonylbenzyl)-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.93 ^b	572.31
A7			2-[7-(4-Methanesulfonylbenzyl)-4-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.02 ^b	559.32
A8			2-[7-(4-Methanesulfonylbenzyl)-4-(4-methylpiperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.41 ^b	572.47
A9			2-[4-(3-Hydroxymethyl-piperidin-1-yl)-7-(4-methanesulfonylbenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.83 ^b	587.32

			ester		
A10			2-[4-(3-Carbamoyl-piperazin-1-yl)-7-(4-methanesulfonylbenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.35 ^b	601.32
A11			2-[4-(4-Hydroxymethyl-piperidin-1-yl)-7-(4-methanesulfonylbenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.73 ^b	587.30
A12			2-[4-(4-Dimethylamino-piperidin-1-yl)-7-(4-methanesulfonylbenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.17 ^b	600.37
A13			2-[4-(4-Hydroxy-3-hydroxymethyl-piperidin-1-yl)-7-(4-methanesulfonylbenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.57 ^b	603.37

A14			2-[4-Dimethylamino-7-(4-methanesulfonylbenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	2.78 ^b	517.30
A15			2-[7-(4-Methanesulfonylbenzyl)-4-methylamino-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	2.64 ^b	503.44
A16			4-Methyl-2-[4-(3-oxo-piperazin-1-yl)-7-(4-sulfamoylbenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	2.78 ^b	573.20
A17			4-Methyl-2-[4-(3-oxo-piperazin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	2.29 ^b	495.25
A18			2-[7-(3,4-Dimethoxybenzyl)-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	3.24 ^b	554.51





A19		Et	2-[7-Ethyl-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.86 ^b	432.26
A20		Et	2-[7-Ethyl-4-(4-sulfamoylbenzylamino)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.77 ^b	518.21
A21			2-[7-(4-Cyano-benzyl)-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.31 ^b	519.20
A22			2-[7-(2-Dimethylamino-ethyl)-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.21 ^b	475.28
A23			2-[7-Carboxymethyl-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.65 ^b	462.22

A24			2-[7-(2-dimethylaminoethyl)-4-(3,4,5-trimethoxybenzylamino)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	2.52 ^b	572.32
A25			4-Methyl-2-[4-(3-oxo-piperazin-1-yl)-7-[4-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	3.07 ^b	562.23
A26			2-[4-(2-Cyclohex-1-enyl-ethylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.69 ^c	520.25
A27			2-[4-[(2,3-Dihydrobenzo[1,4]dioxin-2-ylmethyl)-amino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.61 ^c	560.24
A28			2-[4-(Butoxycarbonylmethyl-amino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.49 ^c	526.27











A29			2-(4-Cyclopentylamino-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino)-4-methylthiazole-5-carboxylic acid ethyl ester	1.46 ^c	480.26	
A30			4-Methyl-2-{4-[(5-methyl-furan-2-ylmethyl)-amino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester	1.47 ^c	506.25	
A31			4-Methyl-2-{4-[3-(2-methyl-piperidin-1-yl)-propylamino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester	1.17 ^c	551.31	
A32			4-Methyl-2-[4-(2-oxo-azepan-3-ylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.38 ^c	523.27	
A33			4-Methyl-2-{7-pyridin-3-ylmethyl-4-[(thiophen-2-ylmethyl)-amino]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-	1.46 ^c	508.19	









			ylamino}-thiazole-5-carboxylic acid ethyl ester		
34			2-[4-(3-Imidazol-1-yl-propylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.08 ^c	520.25
A35			4-Methyl-2-[4-(1-carboxyethyl-piperidin-4-ylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.53 ^c	567.29
A36			2-[4-(6-Dimethylamino-hexylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.19 ^c	539.33
A37			4-Methyl-2-[4-(2-pyridin-4-yl-ethylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.10 ^c	517.24
A38			2-[4-(4-Hydroxybutylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.22 ^c	484.25





			ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester		
A39			2-{4-[(1-Ethyl-pyrrolidin-2-ylmethyl)-amino]-7-pyridin-3-ylmethyl}-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.20 °	523.24
A40			2-[4-(2-Acetylaminoethylamino)-7-pyridin-3-ylmethyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.19 °	497.24
A41			4-Methyl-2-{4-[2-(1-methyl-pyrrolidin-2-yl)-ethylamino]-7-pyridin-3-ylmethyl}-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester	1.13 °	523.30
A42			2-[4-(1-Hydroxymethylbutylamino)-7-pyridin-3-ylmethyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.40 °	498.27








A43			4-Methyl-2-[4-(3-morpholin-4-yl-propylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.10 ^c	539.30
A44			2-[4-(2-(1H-Imidazol-4-yl)-ethylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.11 ^c	506.26
A45			2-[4-((S)-2-Carbamoyl-pyrrolidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.19 ^c	509.22
A46			2-[4-(3-Hydroxy-pyrrolidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.16 ^c	482.25
A47			4-Methyl-2-(4-morpholin-4-yl-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino)-thiazole-5-carboxylic acid ethyl ester	1.32 ^c	482.23



A48			4-Methyl-2-{4-[methyl-(1-methylpiperidin-4-yl)-amino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester	1.14 ^c	523.31
A49			2-[4-(3-Diethylcarbamoyl)piperidin-1-yl]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methylthiazole-5-carboxylic acid ethyl ester	1.63 ^c	577.27
A50			2-{4-[4-(2-Hydroxyethyl)piperidin-1-yl]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methylthiazole-5-carboxylic acid ethyl ester	1.35 ^c	524.26
A51			4-Methyl-2-{4-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester	1.18 ^c	592.30
A52			2-{4-[4-(Furan-2-carbonyl)piperazin-1-yl]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-	1.48 ^c	575.25

			thiazole-5-carboxylic acid ethyl ester		
A53			2-[4-(4-Hydroxy-piperidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.23 ^c	496.26
A54			2-[4-(3-Acetylamino-pyrrolidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.17 ^c	523.28
A55			2-[4-[Ethyl-(1-ethyl-pyrrolidin-3-yl)-amino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.09 ^c	537.31
A56			2-[4-(4-Carbamoyl-piperidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.18 ^c	523.25
A57			4-Methyl-2-[4-(4-carboxyethyl-piperidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-	1.54 ^c	552.28

			carboxylic acid ethyl ester		
A58			2-[4-(4-Acetyl-piperazin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.28 ^c	523.27
A59			2-[7-(2-Benzyl-2-oxoethyl)-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.39 ^b	538.22
A60			2-[7-(2-Hydroxyethyl)-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.44 ^b	448.06
A61			2-[4-(4-Hydroxypiperidin-1-yl)-7-[4-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.50 ^c	563.27
A62			4-Methyl-2-[4-[3-(2-oxo-pyrrolidin-1-yl)-propylamino]-7-[4-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-	1.54 ^c	604.33

			ylamino}-thiazole-5-carboxylic acid ethyl ester		
A63			4-Methyl-2-{4-morpholin-4-yl-7-[4-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester	1.48 ^c	549.32
A64			2-[7-(4-tert-Butoxycarbonylbenzyl)-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.95 ^b	594.07
A65			2-[7-(4-Carboxybenzyl)-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.18 ^b	538.21
A66			4-Methyl-2-{4-[(tetrahydrofuran-2-ylmethyl)-amino]-7-[4-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester	1.64 ^c	563.20


A67			2-{4-[4-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.76 ^c	547.15
A68			2-{4-[4-(4-hydroxybutylamino)-7-[4-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.56 ^c	551.62
A69			4-Methyl-2-[7-[4-(1H-tetrazol-5-yl)-benzyl]-4-(2-thienyl-2-yl-ethylamino)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.76 ^c	589.15
A70			4-Methyl-2-{4-(3-methyl-butylamino)-7-[4-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester	1.76 ^c	549.23
A71			2-{4-(2-Ethoxyethylamino)-7-[4-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic	1.64 ^c	551.19

			acid ethyl ester		
A72			2-{4-(3-Hydroxymethylpiperidin-1-yl)-7-[4-(1H-tetrazol-5-yl)benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methylthiazole-5-carboxylic acid ethyl ester	1.59 ^c	577.22


HPLC conditions used to determine retention times: ^aXterra 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% H_3PO_4 , 5 mL/min, monitoring at 220 nm or 254 nm. ^bYMC CombiScreen 5 μ m C18 column 4.6 x 50 mm, 10-90 % aqueous methanol over 4 min containing 0.1% TFA, 4 mL/min, monitoring at 220 nm or 254 nm. ^cPhenomenex 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% H_3PO_4 , 5 mL/min, monitoring at 220 nm or 254 nm

Example B1

4-Methyl-2-[4-morpholin-4-yl-6-oxo-7-(3,4,5-trimethoxy-benzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester




5

B1**B1.1: 2-Ethoxycarbonyl-succinic acid diethyl ester****B1.1**


10 To a suspension of NaH (1.58 g, 62.5 mmol) in THF (100 mL) was added diethylmalonate (10 g, 62.5 mmol), followed by ethyl bromoacetate (8.18g, 48 mmol) under nitrogen. The reaction mixture was stirred at room temperature for 4 hours and then poured into saturated ammonium chloride solution (200 ml). It was extracted with three portions of ethyl acetate (100 ml). The combined organic phases 15 were washed with brine (100 ml), dried over sodium sulfate and the solvent was removed to yield **B1.1** (13.94 g, 91%). $^1\text{H-NMR}$ (CDCl_3) δ : 4.13-4.28 (6H, m), 3.84 (1H, t, J = 7 Hz), 2.94 (2H, d, J = 7 Hz), 1.24-1.33 (9H, m).

B1.2: 2-(5-Ethoxycarbonylmethyl-4,6-dihydroxy-pyrimidin-2-ylamino)-4-methyl-thiazole-5-carboxylic acid ethyl ester

**B1.2**

5 Sodium (0.766 g, 33.3 mmol) was added to ethanol (50 ml) and stirred at room temperature until the sodium was completely dissolved. To the reaction mixture was added **A1.1** (2.53 g, 11.1 mmol) and **B1.1** (3.0 g, 12.2 mmol) which was heated to 100°C for 7 hrs and then it was cooled to RT. The solid was collected as the desired product **B1.2** (3.234 g, 76%). HPLC: 85%, ret. time = 3.457 min., LC/MS (M+H)⁺ = 10 383.03.

B1.3: 2-(4,6-Dichloro-5-ethoxycarbonylmethyl-pyrimidin-2-ylamino)-4-methyl-thiazole-5-carboxylic acid ethyl ester


**B1.3**

15 A solution of **B1.2** (1.07 g, 0.28 mmol) in POCl₃ (3 ml) was heated to 100°C for 4 hours and then it was cooled to RT and poured into 50 ml of ice-water. It was neutralized with NaOH/water (1/1) to approximately pH 7. The solid was collected by filtration and then it was added to 10 ml of methanol and stirred about 10 20 minutes. The solid was collected to yield the desired product **B1.3** (590 mg, 50%). HPLC: 82%, ret. time = 3.903 min., LC/MS (M+H)⁺ = 418.96.

B1.4: 4-Methyl-2-[4-morpholin-4-yl-6-oxo-7-(3,4,5-trimethoxy-benzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester

A solution of **B1.3** (50 mg, 0.12 mmol), 3,4,5-trimethoxybenzylamine (24 mg, 0.12 mmol), and diisopropylethylamine (17mg, 0.13 mmol) in N-methyl-2-pyrrolidine (0.5 ml) was heated to 100°C for 25 minutes under microwave irradiation. Morpholine (22.5 mg, 0.258 mmol) was then added and the reaction 5 mixture was heated to 180°C for 15 minutes under microwave irradiation. Methanol (2 ml) was added and the mixture was stirred at room temperature for 30 minutes. The solid was collected to afford **B1** (19 mg, 27 %). $^1\text{H-NMR}$ (DMSO) δ : 11.65 (1H, s), 6.66 (2H, s), 4.65 (2H, s), 4.09 (2H, q, $JJ=7$ Hz), 3.73 (2H, s), 3.55-3.65 (14H, m), 3.50 (3H, s), 2.42 (3H, s), 1.12 (3H, t, $J = 7$ Hz). HPLC: 96%, ret. time = 10 3.810 min., LC/MS (M+H) $^+$ = 585.49.

Example B2-B32













15 Examples **B2** to **B32** were prepared in a similar manner to that used for Example **B1** utilizing the appropriate amine replacements.









Table B1











Ex.	Z	R ⁵	Name	HPLC Retention ^a (min)	MS Reported
B2			4-Methyl-2-[6-oxo-4-(3-oxo-piperazin-1-yl)-7-(4-sulfamoylbenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	3.01	586.98











B3			2-[7-(4-Methanesulfonylbenzyl)-6-oxo-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	3.10	586.20
B4			2-[4-(4-Hydroxypiperidin-1-yl)-6-oxo-7-(3,4,5-trimethoxybenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	3.72	599.41
B5			4-Methyl-2-[6-oxo-4-(3-oxo-piperazin-1-yl)-7-(3,4,5-trimethoxybenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	3.52	598.38
B6			4-Methyl-2-[4-morpholin-4-yl-6-oxo-7-(4-sulfamoylbenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	3.32	574.38
B7			2-[4-(4-Hydroxypiperidin-1-yl)-6-oxo-7-(4-sulfamoylbenzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	3.21	588.36





			thiazole-5-carboxylic acid ethyl ester		
B8			4-Methyl-2-[4-(4-methyl-3-oxo-piperazin-1-yl)-6-oxo-7-(4-sulfamoyl-benzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	3.15	601.35
B9			4-Methyl-2-[6-oxo-4-(3-oxo-piperazin-1-yl)-7-(4-[1,2,4]triazol-4-yl-benzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	3.11	575.40
B10			2-[7-(4-Imidazol-1-yl-benzyl)-6-oxo-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.66	574.41
B11			4-Methyl-2-[6-oxo-4-(3-oxo-piperazin-1-yl)-7-[2-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	3.16	576.40

B12			2-{4-(4-Hydroxypiperidin-1-yl)-6-oxo-7-[2-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methylthiazole-5-carboxylic acid ethyl ester	3.39	577.45
B13			4-Methyl-2-{6-oxo-4-(3-oxo-piperazin-1-yl)-7-[3-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester	3.34	576.43
B14			4-Methyl-2-[6-oxo-4-(3-oxo-piperazin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	2.47	509.43
B15			2-{4-(4-Hydroxypiperidin-1-yl)-6-oxo-7-[3-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methylthiazole-5-carboxylic acid ethyl ester	3.53	577.41
B16			4-Methyl-2-[6-oxo-4-(3-oxo-piperazin-1-yl)-7-pyridin-2-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl	2.83	509.43

			ester		
B17			2-[4-(4-Hydroxypiperidin-1-yl)-6-oxo-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	2.76	510.26
B18			2-[4-(4-Hydroxypiperidin-1-yl)-6-oxo-7-pyridin-2-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	3.01	510.24
B19			4-Methyl-2-[6-oxo-4-(3-oxo-piperazin-1-yl)-7-pyridin-4-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	2.34	509.37
B20			4-Methyl-2-(4-morpholin-4-yl-6-oxo-7-pyridin-4-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino)-thiazole-5-carboxylic acid ethyl ester	2.69	496.38

B21			2-[4-(4-Hydroxypiperidin-1-yl)-6-oxo-7-pyridin-4-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	2.63	510.27
B22			4-Methyl-2-[6-oxo-4-(3-oxo-piperazin-1-yl)-7-[4-(1H-tetrazol-5-yl)benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	3.30	576.16
B23			2-[4-(4-Hydroxypiperidin-1-yl)-6-oxo-7-[4-(1H-tetrazol-5-yl)benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	3.47	577.19
B24			4-Methyl-2-[4-morpholin-4-yl-6-oxo-7-[4-(1H-tetrazol-5-yl)benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	3.62	563.26
B25			2-[7-(4-Cyano-benzyl)-4-(4-hydroxypiperidin-1-yl)-6-oxo-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	3.55	534.13

			acid ethyl ester		
B26			2-[4-(4-Hydroxy-piperidin-1-yl)-7-(4-methyl-benzyl)-6-oxo-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.95	523.15
B27			2-[7-Benzyl-4-(4-hydroxy-piperidin-1-yl)-6-oxo-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.78	509.14
B28			2-[7-(3-Fluoro-benzyl)-4-(4-hydroxy-piperidin-1-yl)-6-oxo-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.82	527.17
B29			2-[4-(4-Hydroxy-piperidin-1-yl)-7-(3-methoxy-benzyl)-6-oxo-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.80	539.17
B30			2-[7-(3,4-Dimethoxy-benzyl)-4-(4-hydroxy-piperidin-1-yl)-6-oxo-5,6-dihydro-pyrrolo[2,3-	3.61	569.16


			d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester		
B31			2-[4-(4-Hydroxy-piperidin-1-yl)-7-(4-methoxy-benzyl)-6-oxo-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.76	539.17
B32			2-[7-(4-Bromo-benzyl)-4-(4-hydroxy-piperidin-1-yl)-6-oxo-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	4.10	587.02

HPLC conditions used to determine retention times: ^aYMC CombiScreen 5 μ m C18 column 4.6 x 50 mm, 10-90 % aqueous methanol over 4 min containing 0.1% TFA, 4 mL/min, monitoring at 220 nm or 254 nm

5

Example B33

2-[4-(4-Hydroxy-piperidin-1-yl)-6-oxo-7-(4-thiophen-3-yl-benzyl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester




B33

10 A degassed solution of 3-thiopheneboronic acid (4.4 mg, 0.034 mmol) in 0.4 M sodium carbonate solution (0.5 ml) was added dropwise to the degassed suspension of **B32** (20 mg, 0.034 mmol) and tetrakis(triphenylphosphine)palladium(0) (20 mg, 0.017 mmol) in acetonitrile (0.5

ml) at 90°C under nitrogen. The reaction mixture was heated at 90°C for 30 minutes. The hot suspension was filtered to remove the catalyst and the filtrate was concentrated to afford the crude product which was purified by preparative TLC (silica, 2:1 EtOAc: hexanes) to yield **B33** (6.2 mg, 31 %). ¹H-NMR (DMSO) δ: 5 11.68 (1H, s), 7.82-7.86 (1H, m), 7.61-7.69 (3H, M), 7.51-7.54 (1H, m), 7.43 (2H, d, J= 8 Hz), 4.86 (2H, s), 4.22 (2H, q, JJ=7Hz), 4.08-4.18 (2H, m), 3.84 (2H, s), 3.74-3.81 (1H, m), 3.33-3.35 (2H, m, merge with water), 2.51 (3H, s, merge with DMSO), 1.78-1.87 (2H, m), 1.36-1.48 (2H, m), 1.27 (3H, t, J = 7 Hz). HPLC:>95%, ret. time = 4.120 min., LC/MS (M+H)⁺ = 591.11.

10

Example B34-B36



15 Examples **B34** and **B35** were prepared in a similar manner to that used for Example **B33** utilizing the appropriate heteroarylboronic acid replacement. Example **B36** was isolated as a side product during the preparation of Example **B35**.

Table B2

Ex.	R ⁵	Name	HPLC Retention ^a (min)	MS Reported
B34		2-[7-[4-(3,5-Dimethyl-isoxazol-4-yl)-benzyl]-4-(4-hydroxy-piperidin-1-yl)-6-oxo-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.81	604.14


B35		2-[7-[4-(1-tert-Butoxycarbonyl-1H-pyrrol-2-yl)-benzyl]-4-(4-hydroxy-piperidin-1-yl)-6-oxo-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	4.25	674.14
B36		2-{4-(4-Hydroxy-piperidin-1-yl)-6-oxo-7-[4-(1H-pyrrol-2-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.80	574.16

HPLC conditions used to determine retention times: ^aYMC CombiScreen 5 μ m C18 column 4.6 x 50 mm, 10-90 % aqueous methanol over 4 min containing 0.1% TFA, 4 mL/min, monitoring at 220 nm or 254 nm

5

Example B37

2-[7-(4-Carboxy-benzyl)-6-oxo-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester

**B37**


10

A solution of **B1.3** (223 mg, 053 mmol), t-butyl(4-aminomethyl)benzoate (110 mg, 0.53 mmol), and diisopropylethylamine (108uL, 0.56 mmol) in N-methyl-

2-pyrrolidine (2 ml) was heated to 100°C for 20 minutes under microwave irradiation. Piperazin-2-one (113 mg, 1.12 mmol) was then added. The reaction mixture was heated to 180°C for 10 minutes under microwave irradiation, 10 ml of methanol was added and the mixture stirred for 5 minutes. The solid which was 5 collected was dissolved in dichloromethane (0.5 ml) and TFA (0.5 ml) at 0-5°C. The reaction mixture was warmed to RT, stirred for 30 minutes and concentrated. Methanol (2 ml) was added and the mixture stirred for 10 minutes. The solid was collected to afford **B37** (97.3 mg, 73%). $^1\text{H-NMR}$ (DMSO) δ : 11.84 (1H, s), 8.28 (1H, s), 7.99 (2H, d, J = 8 Hz), 7.57 (2H, d, J = 8 Hz), 5.04 (2H, s), 4.42 (2H, s), 10 4.32 (2H, q, J =7Hz), 4.07 (2H, s), 3.96-4.02 (2H, m), 3.55-3.75 (2H, m), 2.61 (3H, s, merge with DMSO), 1.38 (3H, t, J = 7 Hz). HPLC:89%, ret. time = 3.31 min., LC/MS (M+H) $^+$ = 552.05.

Example B38

15 2-[7-(4-Dimethylcarbamoyl-benzyl)-6-oxo-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester




B38

20 A solution of **B37** (15 mg, 0.027 mmol) dimethylamine hydrochloride (2.66 mg, 0.0326 mmol) and diisopropylethylamine (11.5 mg, 0.114 mmol) in DMF (1 ml) was treated with bis(oxo-3-oxazolidinyl) phosphinic chloride (21 mg, 0.081 mmol) and the reaction mixture was stirred at RT for 1 h. The reaction mixture was purified by preparative HPLC to afford **B38** (7.3 mg, 47%). $^1\text{H-NMR}$ (CDCl₃) δ : 7.41 (2H, d, J = 8 Hz), 7.18 (2H, d, J = 8 Hz), 6.47 (1H, s), 4.16- 4.25 (4H, m), 25

3.83-3.90 (2H, m), 3.56 (2H, s), 3.35-3.41 (2H, m), 2.92 (3H, s), 2.78 (3H, s), 2.52 (3H, s), 1.22 (3H, t, $J = 7$ Hz). HPLC: >90%, ret. time = 3.160 min., LC/MS $(M+H)^+ = 579.15$.

5

Example B39-B43






Examples B39 to B43 were prepared in a similar manner to that used for Example B38 utilizing the appropriate amine replacement.

10

Table B3

Ex.	R^5	Name	HPLC Retention ^a (min)	MS Reported
B39		2-[7-[4-(4-Hydroxypiperidine-1-carbonyl)-benzyl]-6-oxo-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.12	635.12
B40		4-Methyl-2-[7-[4-(morpholine-4-carbonyl)-benzyl]-6-oxo-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	3.15	621.12


B41		2-[7-(4-Isobutylcarbamoylbenzyl)-6-oxo-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.45	607.19
B42		2-[7-[4-(3-Hydroxypyrrolidine-1-carbonyl)-benzyl]-6-oxo-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.05	621.13
B43		2-[7-{4-[(2-Hydroxyethyl)-methylcarbamoyl]-benzyl}-6-oxo-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.07	609.19

HPLC conditions used to determine retention times: ^aYMC CombiScreen 5 μ m C18 column 4.6 x 50 mm, 10-90 % aqueous methanol over 4 min containing 0.1% TFA, 4 mL/min, monitoring at 220 nm or 254 nm

5

Example C1


2-[8-(4-Methanesulfonyl-benzyl)-4-(1-tert-butoxycarbonyl-piperazin-4-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester



C1

C1.1: 4-(2-Chloro-pyrido[2,3-d]pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester

5




C1.1

A mixture of 2,4-dichloro-pyrido[2,3-d]pyrimidine (150 mg, 0.75 mmol, 1 eq) [prepared from 2-aminonicotinic acid by the methods of Robins *et al.* (*J. Am. Chem. Soc.* **1955**, 77, 1045.) and Oakes *et al.* (*J. Chem. Soc.* **1956**, 1045.)], N-*t*-butoxycarbonyl piperazine (147 mg, 0.787 mmol, 1.05 eq) and Hunig's base (0.39 mL, 2.25 mmol, 3 eq) in ethanol (2.5 mL) was stirred at rt for 17 hr. The white solid was collected by filtration, washed with water and cold ethanol, and dried to afford C1.1 (105 mg, 40% yield). LC/MS: 350.41 [M+H]⁺; HPLC: >95 % at 1.44 min (Xterra 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% phosphoric acid, 5 mL/min, monitoring at 254 nm).

C1.2: C4-(2-Chloro-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester

15

20

**C1.2**

A mixture of **C1.1** (41 mg, 0.117 mmol, 1 eq), PtO₂ (2.7 mg, 0.0117 mmol, 0.1 eq) and ethanol (1 mL) was stirred under a H₂ atmosphere (1 atm) for 4.5 h. The 5 mixture was filtered through celite and the filtrate was concentrated to afford **C1.2** (41 mg, quant.) as a white solid. LC/MS: 354.42 [M+H]⁺; HPLC: 96 % at 3.43 min (Phenomenex Luna 5 μ m C18 column 4.6 x 50 mm, 10-90 % aqueous methanol over 4 min containing 0.2% phosphoric acid, 4 mL/min, monitoring at 254 nm). ¹H NMR (400 MHz, CD₃OD): δ 3.41 (m, 4 H), 3.24 (m, 2 H), 3.16 (m, 4 H), 2.46 (m, 2 H), 10 1.70 (m, 2 H), 1.37 (s, 9 H).

C1.3: 2-[8-(4-Methanesulfonyl-benzyl)-4-(1-tert-butoxycarbonyl-piperazin-4-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester

15 A solution of **C1.2** (40 mg, 0.113 mmol, 1 eq) in DMF (1mL) at 0 °C was treated with NaH (60% in mineral oil, 5 mg, 0.124 mmol, 1.1 eq). After stirring at 0 °C for 10 min, 4-methylsulfonylbenzyl chloride (25 mg, 0.124 mmol, 1.1 eq) was added; the reaction mixture was warmed to rt, stirred for 1.5 h and then poured onto ice. The solid was collected by filtration, washed with water and dried to afford (42 mg, 71% yield) a light yellow solid. HPLC: >95 % at 1.81 min (Xterra 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% phosphoric acid, 5 mL/min, monitoring at 254 nm).

20 To a mixture of this product (40 mg, 0.0766 mmol, 1 eq) and ethyl 2-amino-4-methylthiazole-5-carboxylate (28.5 mg, 0.153 mmol, 2 eq) in N,N-dimethylacetamide (0.8 mL) in a 2-dram vial was added tris(dibenzylideneacetone)dipalladium(0) (7 mg, 25 0.0077 mmol, 0.1 eq), 2-(di-t-butylphosphino)biphenyl (6.9 mg, 0.023 mmol, 0.3 eq)


and potassium phosphate (33 mg, 0.153 mmol, 2 eq). The vial was purged with N₂, sealed and heated in a 105 °C oil bath for 2.5 h. The reaction mixture was cooled to rt, filtered and concentrated in vacuo. Column chromatography (SiO₂, 60% ethyl acetate/heptane → ethyl acetate) gave **C1** (35 mg, 68% yield) as a yellow solid.

5 LC/MS: 672.44 [M+H]⁺; HPLC: 96 % at 1.87 min (Xterra 5 μm C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% phosphoric acid, 5 mL/min, monitoring at 254 nm). ¹H NMR (500 MHz, DMSO-d₆): δ 11.26 (br s, 1 H), 7.87 (d, *J* = 8.2 Hz, 2 H), 7.57 (d, *J* = 8.2 Hz, 2 H), 4.99 (s, 2 H), 4.15 (q, *J* = 6.6 Hz, 2 H), 3.45 (m, 4 H), 3.36 (m, 2 H), 3.24 (m, 4 H), 3.17 (s, 3 H), 2.54 (m, 2 H), 2.47 (s, 10 3 H), 1.79 (m, 2 H), 1.42 (s, 9 H), 1.21 (m, 3 H).

Example C2

2-[8-(4-Methanesulfonyl-benzyl)-4-piperazin-1-yl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester


15



C2

A solution of **C1** (17.6 mg, 0.026 mmol, 1 eq) in dichloromethane (1.5 mL) was cooled to 0 °C and trifluoroacetic acid (0.2 mL) was added dropwise. The 20 reaction mixture was stirred at 0 °C for 4.5 h and then ether (ca. 2mL) was added. The precipitated beige solid was collected by filtration and dried to afford **C2** (7.5 mg, 42% yield) as the trifluoroacetic acid salt. LC/MS: 572.44 [M+H]⁺; HPLC: >95 % at 1.24 min (Xterra 5 μm C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% phosphoric acid, 5 mL/min, monitoring at 254 nm).





25

Example C3-C7

Example C3 was prepared in a similar manner to that used for Example C2
 5 utilizing dimethylamine in place of N-*t*-butoxycarbonyl piperazine in step C1.1.
 Examples C4 to C7 were prepared in a similar manner to that used for Example C2
 utilizing the appropriate replacement for 4-methylsulfonylbenzyl chloride in step
 C1.3.

Table C1

Ex.	Z	R ⁵	Name	HPLC Retention (min) ^a	MS Reported
C3			2-[4-Dimethylamino-8-(4-methanesulfonylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.37	531.55
C4			2-(8-Benzyl-4-piperazin-1-yl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino)-4-methylthiazole-5-carboxylic acid ethyl ester	1.55	494.35
C5			2-[8-(4-Fluoro-benzyl)-4-piperazin-1-yl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.57	512.27


C6			4-Methyl-2-(4-piperazin-1-yl-8-pyridin-3-ylmethyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino)-thiazole-5-carboxylic acid ethyl ester	0.95	495.37
C7			4-Methyl-2-[4-piperazin-1-yl-8-(3,4,5-trimethoxy-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.40	584.05

HPLC conditions used to determine retention times: ^aXterra 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% H₃PO₄, 5 mL/min, monitoring at 220 nm or 254 nm.

5


Example C8

2-[4-(4-Hydroxy-piperidin-1-yl)-8-(3,4,5-trimethoxy-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester




C8

10

C8.1: 2-But-3-enyl-malonic acid diethyl ester**C8.1**

A mixture of sodium hydride (60% in mineral oil, 435 mg, 10.87 mmol, 1.1 eq) in DMF (20 mL) was treated dropwise with diethyl malonate (1.5 mL, 9.88 mmol, 1.0 eq). The reaction mixture was then cooled to 0 °C and 4-bromo-1-butene (1.0 mL, 9.88 mmol, 1 eq) was added dropwise. The reaction mixture was warmed to rt, stirred for 3 days and then partitioned between ether and water. The layers were separated, the aqueous layer was extracted with ether (2 x 50 mL) and the combined organic phases were washed with water (2 x) and brine, dried over MgSO₄ and concentrated. Column chromatography (SiO₂, 5 % ether/heptane) gave **C8.1** (1.51 g, 71% yield) as a colorless oil. ¹H NMR (400 MHz, DMSO-*d*₆): δ 5.77 (m, 1 H), 5.00 (m, 2 H), 4.13 (q, *J* = 7.1 Hz, 4 H), 3.43 (t, *J* = 7.4 Hz, 1 H), 2.02 (m, 2 H), 1.84 (m, 2 H), 1.17 (t, *J* = 7.1 Hz, 6 H).

C8.2: 2-(5-But-3-enyl-4,6-dioxo-1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-4-methyl-thiazole-5-carboxylic acid ethyl ester




20

C8.2

To a solution of NaOEt in EtOH [prepared by dissolving Na (101 mg, 4.38 mmol, 2.5 eq) in 12 mL of absolute ethanol] was added **A1.1** (400 mg, 1.75 mmol, 1 eq) and the mixture was stirred at rt for 10 min. A solution of **C8.1** (376 mg, 1.75 mmol, 1 eq) in ethanol (5 mL) was added dropwise, the reaction mixture was heated at reflux for 20.5 h and then cooled and poured onto a mixture of ice and 10% aq H₂SO₄. The solid was collected by filtration, washed with water and dried to afford **C8.2** (430 mg, 70% yield) as a white solid. LC/MS: 351.57 [M+H]⁺; HPLC: >95 %

at 1.74 min (Xterra 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% phosphoric acid, 5 mL/min, monitoring at 254 nm).

5 **C8.3: 2-(5-But-3-enyl-4,6-dichloro-pyrimidin-2-ylamino)-4-methyl-thiazole-5-**
carboxylic acid ethyl ester




C8.3

10 A mixture of **C8.2** (430 mg, 1.23 mmol, 1 eq) and POCl_3 (4 mL) was heated in a 100 $^{\circ}\text{C}$ oil bath for 28 h. The reaction mixture was poured onto ice, neutralized with 2 N NaOH, and extracted with ethyl acetate. The organic phase was washed with sat. NaHCO_3 and brine, dried over MgSO_4 and concentrated to afford **C8.3** (383 mg, 80% yield) as a beige solid. LC/MS: 387.22 $[\text{M}+\text{H}]^+$; HPLC: >95 % at 2.15 min (Xterra 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% phosphoric acid, 5 mL/min, monitoring at 254 nm). ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ 12.65 (br s, 1 H), 5.90 (m, 1 H), 5.03 (m, 2 H), 4.27 (q, $J = 7.1$ Hz, 2 H), 2.85 (m, 2 H), 2.54 (s, 3 H), 2.31 (m, 2 H), 1.29 (t, $J = 7.1$ Hz, 3 H).

15

20 **C8.4: 2-[4,6-Dichloro-5-(3,4-dihydroxy-butyl)-pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester**




C8.4

25 To a mixture of **C8.3** (383 mg, 0.988 mmol, 1 eq) and NMO monohydrate (267 mg, 1.976 mmol, 2 eq) in THF/water (9:1, 10 mL) at 0 $^{\circ}\text{C}$ was added a solution of OsO_4 in water (4 wt %, 0.61 mL, 0.0988 mmol, 0.1 eq). The reaction mixture was

warmed to rt, stirred for 16.5 h and then quenched with a solution of 300 mg of NaHSO₃ in 20 mL of water. The off-white solid was collected by filtration, washed with water and ether, and dried to afford **C8.4** (280 mg, 67% yield). LC/MS: 421.42 [M+H]⁺; HPLC: 96 % at 1.66 min (Xterra 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% phosphoric acid, 5 mL/min, monitoring at 254 nm).

C8.5: 2-[4,6-Dichloro-5-(3-oxo-propyl)-pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester


10

**C8.5**

A mixture of **C8.4** (30 mg, 0.0712 mmol, 1 eq) in THF/methanol (1:1, 1 mL) at 0 °C was treated with Pb(OAc)₄ (35 mg, 0.0783 mmol, 1.1 eq). After 3 h at 0 °C, the reaction mixture was diluted with ethyl acetate, washed with water and brine, dried over Na₂SO₄ and concentrated to afford **C8.5** (28 mg, quantitative yield) as a white solid. HPLC: >95 % at 1.80 min (Xterra 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% phosphoric acid, 5 mL/min, monitoring at 254 nm). ¹H NMR (400 MHz, CDCl₃): δ 9.88 (s, 1 H), 4.36 (q, J = 7.1 Hz, 2 H), 3.17 (m, 2 H), 2.78 (m, 2 H), 2.73 (s, 3 H), 1.40 (t, J = 7.1 Hz, 3 H).

C8.6: 2-[4-Chloro-8-(3,4,5-trimethoxy-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester


25

**C8.6**

To a solution of **C8.5** (500 mg, 1.28 mmol) in THF (14 mL), was added 3,4,5-trimethoxybenzylamine (0.230mL, 1.35 mmol), $\text{Na(OAc)}_3\text{BH}$ (407mg, 1.92 mmol) and AcOH (0.073 mL, 1.28 mmol). The reaction was stirred at room temperature for 1hr, and then quenched with NaHCO_3 and extracted with EtOAc. The organic layer was washed with 1N HCl and brine, dried (Na_2SO_4), filtered and concentrated in vacuo to yield 641mg (94% yield) of **C8.6** as a dark tan solid. MS ,(ES), m/e : 535 (MH+). ^1H NMR (DMSO-d₆): 1.11 (t, 3H, J = 7.0 Hz), 1.88 (m, 2H), 2.52 (s, 3H), 2.66 (t, 2H, J = 6.0 Hz), 3.40 (t, 2H, J = 5.0 Hz), 3.65 (s, 2H), 3.73 (s, 9H), 4.13 (q, 2H, J = 7.0Hz), 6.69 (s, 2H), 11.7 (s, 1H).

C8.7: 2-[4-(4-Hydroxy-piperidin-1-yl)-8-(3,4,5-trimethoxy-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester











To a solution of **C8.6** (500 mg, 0.940 mmol) in n-BuOH (2 mL), was added 4-hydroxypiperidine (208 mg, 2.1 mmol), and Hunig's base (738 mL, 4.1mmol). The reaction mixture was heated at 200°C under microwave irradiation for 30 min and then diluted with MeOH and purified by preparative HPLC to afford **C8**. MS ,(ES), m/e : 598.73 (MH+). HPLC: 1.59 min (Phenomenex 5 μm C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% phosphoric acid, 5 mL/min, monitoring at 254 nm).







Example C9-C82







Examples C9 to C82 were prepared in a similar manner to that used for
5 Example C8 utilizing the appropriate amine replacements.










Table C2









Ex.	Z	R ⁵	Name	HPLC Retention (min)	MS Reported
C9			4-Methyl-2-[4-(4-methyl-piperazin-1-yl)-8-(3,4,5-trimethoxybenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.38 ^a	598.55
C10			2-[4-(1-carboxyethyl)piperazin-4-yl)-8-(3,4,5-trimethoxybenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.77 ^b	655.78
C11			2-[4-(2-Acetylaminooethylamino)-8-(3,4,5-trimethoxybenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.63 ^b	599.71









C12			2-[4-(3-carboxyethyl-piperidin-1-yl)-8-(3,4,5-trimethoxybenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.85 ^b	654.79
C13			4-Methyl-2-[8-(3,4,5-trimethoxybenzyl)-4-(3,4,5-trimethoxybenzylamino)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.67 ^a	694.81
C14			4-Methyl-2-[4-(3-oxo-piperazin-1-yl)-8-(4-(1H-tetrazol-5-yl)-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.53 ^b	577.23
C15			2-[4-(4-Hydroxypiperidin-1-yl)-8-[4-(1H-tetrazol-5-yl)-benzyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.55 ^b	576.22
C16			2-[4-[Ethyl-(2-methoxyethyl)-amino]-8-(3,4,5-trimethoxybenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-	1.53 ^b	600.74

			thiazole-5-carboxylic acid ethyl ester		
C17			4-Methyl-2-[4-morpholin-4-yl-8-(3,4,5-trimethoxybenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.68 ^b	584.70
C18			2-[4-(4-hydroxymethylpiperidin-1-yl)-8-(3,4,5-trimethoxybenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.63 ^b	612.75
C19			4-Methyl-2-[4-(3-oxo-piperazin-1-yl)-8-(3,4,5-trimethoxybenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.62 ^b	597.70
C20	Cl		2-[4-Chloro-8-(1,1,3-trioxo-2,3-dihydro-1H-1λ ⁶ -benzo[d]isothiazol-5-ylmethyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.67 ^c	550.14









C21			4-Methyl-2-[4-morpholin-4-yl-8-(1,1,3-trioxo-2,3-dihydro-1H-1λ ⁶ -benzo[d]isothiazol-5-ylmethyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.43 ^b	600.27
C22			4-Methyl-2-[8-(3-(morpholine-4-carbonyl)-4-sulfamoylbenzyl)-4-morpholin-4-yl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.43 ^b	687.32
C23			2-[4-(4-Hydroxypiperidin-1-yl)-8-(4-sulfamoylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.22 ^c	588.28
C24			2-[4-(2-Acetylaminooethylamino)-8-(4-sulfamoylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.24 ^c	589.25











C25			4-Methyl-2-[4-morpholin-4-yl-8-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.46 ^b	574.20
C26			4-Methyl-2-[8-(4-sulfamoyl-benzyl)-4-(3,4,5-trimethoxybenzylamino)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.58 ^b	684.22
C27			4-Methyl-2-[4-methylamino-8-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.44 ^b	518.19
C28			4-Methyl-2-[4-(3-oxo-piperazin-1-yl)-8-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.45 ^b	587.15
C29	Cl		2-{4-Chloro-8-[4-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-benzyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino}-4-methylthiazole-5-carboxylic acid	1.76 ^b	528.94









			acid ethyl ester		
C30			2-{4-(4-Hydroxypiperidin-1-yl)-8-[4-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-benzyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino}-4-methylthiazole-5-carboxylic acid ethyl ester	1.61 ^b	593.49
C31			2-[8-(4-Ethanesulfonylamino-benzyl)-4-(3-oxo-piperazin-1-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.59 ^b	614.75
C32			2-[4-(2-Acetylaminooethylamino)-8-(4-ethanesulfonylamino-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.59 ^b	616.77
C33			2-[4-(4-Hydroxypiperidin-1-yl)-8-(4-methanesulfonylamino carbonyl-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.42 ^c	629.76









C34			2-[8-(4-Methanesulfonylamino carbonyl-benzyl)-4-(3-oxo-piperazin-1-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.50 ^b	628.73
C35			2-[4-(2-Acetylaminomethylamino)-8-(4-methanesulfonylamino carbonyl-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.54 ^b	630.75
C36			2-[4-(4-Hydroxymethylpiperidin-1-yl)-8-(4-methanesulfonylamino carbonyl-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.55 ^b	643.79
C37			4-Methyl-2-(4-morpholin-4-yl-8-pyridin-4-ylmethyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino)-thiazole-5-carboxylic acid ethyl ester	1.37 ^b	495.61











C38			4-Methyl-2-[4-(3-oxo-piperazin-1-yl)-8-pyridin-4-ylmethyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.32 ^b	508.61
C39			2-[4-(2-Acetylaminooethylamino)-8-pyridin-4-ylmethyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.25 ^b	510.62
C40			4-Methyl-2-{4-morpholin-4-yl-8-[4-(propane-1-sulfonylamino)-benzyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester	1.68 ^b	615.78
C41			2-{4-(4-Hydroxypiperidin-1-yl)-8-[4-(propane-1-sulfonylamino)-benzyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.64 ^b	629.81








C42			4-Methyl-2-{4-(3-oxo-piperazin-1-yl)-8-[4-(propane-1-sulfonylamino)-benzyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester	1.66 ^b	628.78
C43			2-{4-(4-Hydroxymethyl-piperidin-1-yl)-8-[4-(propane-1-sulfonylamino)-benzyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.68 ^b	643.83
C44			2-{4-(2-Acetylaminomethylamino)-8-[4-(propane-1-sulfonylamino)-benzyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.66 ^b	630.79
C45			2-[8-(4-Carbamoylbenzyl)-4-morpholin-4-yl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.51 ^b	537.65

C46			2-[8-(4-Carbamoyl-benzyl)-4-(3-oxo-piperazin-1-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.49 ^b	550.64
C47			2-[4-(2-Acetylaminomethylamino)-8-(4-carbamoyl-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.52 ^b	552.66
C48			2-[8-(4-Carbamoyl-benzyl)-4-(4-hydroxypiperidin-1-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.57 ^b	551.67
C49			4-Methyl-2-[8-(4-methylsulfamoyl-benzyl)-4-morpholin-4-yl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.55 ^b	587.72
C50			4-Methyl-2-[4-morpholin-4-yl-8-[4-(propane-2-sulfonylamino)-benzyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.67 ^b	615.78

C51			2-[4-(4-Hydroxymethyl-piperidin-1-yl)-8-[4-(propane-2-sulfonylamino)-benzyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.66 ^b	643.83
C52			2-[4-(2-Acetylaminomethylamino)-8-[4-(propane-2-sulfonylamino)-benzyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.64 ^b	630.79
C53			4-Methyl-2-[4-(3-oxo-piperazin-1-yl)-8-[4-(propane-2-sulfonylamino)-benzyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester	1.63 ^b	628.78
C54			2-[4-(4-Hydroxypiperidin-1-yl)-8-[4-(propane-2-sulfonylamino)-benzyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.66 ^b	629.81











C55			2-[4-(4-Hydroxypiperidin-1-yl)-8-(4-isobutylcarbamoylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.68 ^d	607.78
C56			2-[4-(2-Acetylaminooethylamino)-8-(4-isobutylcarbamoylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.73 ^b	608.77
C57			2-[4-Isobutylamino-8-(4-isobutylcarbamoylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.88 ^b	579.77
C58			2-[8-(4-Isobutylcarbamoylbenzyl)-4-morpholin-4-yl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.74 ^b	593.75

C59			2-[8-(4-Ethanesulfonylamino-benzyl)-4-(4-hydroxy-piperidin-1-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.61 ^b	615.78
C60			2-[8-(4-Ethanesulfonylamino-benzyl)-4-morpholin-4-yl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.63 ^b	601.75
C61			2-[8-(4-Ethanesulfonylamino-benzyl)-4-isobutylamino-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.81 ^b	587.77
C62			2-[8-(4-Ethanesulfonylamino-benzyl)-4-(3,4,5-trimethoxybenzylamino)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.72 ^b	711.87
C63			2-(4-Isobutylamino-8-pyridin-4-ylmethyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino)-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.50 ^b	481.62

			acid ethyl ester		
C64			2-[4-(4-Hydroxypiperidin-1-yl)-8-(6-trifluoromethylpyridin-3-ylmethyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.76 ^b	578.71
C65			2-[4-(2-Acetylaminethylamino)-8-(6-trifluoromethylpyridin-3-ylmethyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.68 ^b	579.15
C66			2-[8-{4-[Ethyl-(2-hydroxyethyl)carbamoyl]-benzyl}-4-(3-hydroxy-pyrrolidin-1-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.47 ^b	609.75
C67			2-[8-{4-[Ethyl-(2-hydroxyethyl)carbamoyl]-benzyl}-4-(3,4,5-trimethoxybenzylamino)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.58 ^c	719.87

C68			2-(4-(2-Acetylaminooethylamino)-8-{4-[ethyl-(2-hydroxyethyl)-carbamoyl]-benzyl}-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino)-4-methylthiazole-5-carboxylic acid ethyl ester	1.48 ^c	624.77
C69			2-(8-{4-[Ethyl-(2-hydroxyethyl)-carbamoyl]-benzyl}-4-isobutylamino-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino)-4-methylthiazole-5-carboxylic acid ethyl ester	1.62 ^b	595.77
C70			2-(4-[Ethyl-(2-hydroxyethyl)-amino]-8-{4-[ethyl-(2-hydroxyethyl)-carbamoyl]-benzyl}-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino)-4-methylthiazole-5-carboxylic acid ethyl ester	1.58 ^b	611.77
C71			2-(8-{4-[Ethyl-(2-hydroxyethyl)-carbamoyl]-benzyl}-4-morpholin-4-yl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino)-4-methylthiazole-5-carboxylic acid ethyl ester	1.58 ^b	609.75

C72			2-[8-{4-[Ethyl-(2-hydroxy-ethyl)-carbamoyl]-benzyl}-4-(3-oxo-piperazin-1-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.57 ^b	622.75
C73			2-[4-(4-Hydroxypiperidin-1-yl)-8-(4-methylsulfamoylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.51 ^b	601.75
C74			2-[8-[4-(1,1-Dioxo-1λ⁶-thiomorpholine-4-carbonyl)-benzyl]-4-(4-hydroxypiperidin-1-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.49 ^b	669.83
C75			4-Methyl-2-[8-(4-methylsulfamoylbenzyl)-4-(3-oxo-piperazin-1-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.54 ^b	600.72

C76			2-[4-(1-Hydroxymethyl-2-methyl-propylamino)-8-(4-methylsulfamoylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.68 ^b	603.77
C77			2-[4-(2-Acetylaminooethylamino)-8-(4-methylsulfamoylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.55 ^b	602.74
C78			2-[4-(2-Hydroxyethylamino)-8-(4-methylsulfamoylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.51 ^b	561.69
C79			2-[4-[Ethyl-(2-hydroxyethyl)-amino]-8-(4-methylsulfamoylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.53 ^b	589.74
C80			2-[4-(4-Carbamoylpiperidin-1-yl)-8-(4-methylsulfamoylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-	1.47 ^d	628.78


			thiazole-5-carboxylic acid ethyl ester		
C81			2-[4-(3-Dimethylamino-propylamino)-8-(4-methylsulfamoylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.42 ^b	602.78
C82			2-[4-(3-Hydroxypiperidin-1-yl)-8-(4-methylsulfamoylbenzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methylthiazole-5-carboxylic acid ethyl ester	1.48 ^b	587.72

HPLC conditions used to determine retention times: ^aXterra 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% H_3PO_4 , 5 mL/min, monitoring at 220 nm or 254 nm. ^bPhenomenex 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% H_3PO_4 , 5 mL/min, monitoring at 220 nm or 254 nm. ^cYMC CombiScreen 5 μ m C18 column 4.6 x 50 mm, 10-90 % aqueous methanol over 4 min containing 0.1% TFA, 4 mL/min, monitoring at 220 nm or 254 nm. ^dPhenomenex 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.1% TFA, 5 mL/min, monitoring at 220 nm or 254 nm

10

Example C83


4-Methyl-2-(4-morpholin-4-yl-8-(2-sulfamoylamino-ethyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino)-thiazole-5-carboxylic acid ethyl ester



C83

C83.1: 2-[8-(2-tert-Butoxycarbonylamino-ethyl)-4-chloro-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester


5



C83.1

Intermediate **C83.1** was prepared in an analogous manner to **C8.6** with the exception that 3,4,5-trimethoxybenzylamine was replaced by *t*-butyl *N*-(2-aminoethyl)carbamate. HPLC: >95% (Phenomenex 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.1% TFA, 5 mL/min, monitoring at 254 nm) ret. time = 1.43 min., LC/MS ($M+H$)⁺ = 498.16.

C83.2: 2-[8-(2-amino-ethyl)-4-chloro-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester




C83.2

Trifluoroacetic acid (20% solution in dichloromethane, 10 mL) was added in one portion to **C83.1** (250 mg, 0.42 mmol) at room temperature under a nitrogen atmosphere. After stirring overnight, toluene (1 mL) was added and the solution was concentrated in vacuo. Two subsequent additions of toluene (2 x 5 mL) followed by 5 concentration in vacuo left the crude trifluoroacetic acid salt of **C83.2** as a yellow residue (210mg, 98%), which was used immediately without characterisation.

C83.3: 2-[8-(2-t-Butoxycarbonyl sulfamoylamino-ethyl) 4-chloro-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester


10



C83.3

Chlorosulfonyl isocyanate (0.076 mL, 0.87mmol) was dissolved in dry dichloromethane (5 mL) and cooled in an ice-bath, and *tert*-butyl alcohol (0.064g, 15 0.87mmol) added dropwise. This solution was allowed to stir for 1hr and was then added to a mixture of the TFA salt of **C83.2** (0.39g, 0.79mmol) and triethylamine (0.24mL, 1.7mmol) in THF (10mL) under a nitrogen atmosphere. After stirring at room temperature overnight, the reaction mixture was quenched by the addition of water (10mL). The aqueous phase was extracted with ethyl acetate (3 x 15mL), and 20 the combined organics were then dried (MgSO_4) and evaporated in vacuo. The crude product was purified by column chromatography using 1:1 hexane:ethyl acetate as eluent to give **C83.3** (0.26g, 56%) as a white solid. $^1\text{H-NMR}$ (DMSO-d_6) δ : 4.23 (2H, q, J = 8 Hz), 3.78-3.69 (2H, m), 3.50-3.36 (4H, m), 2.64-2.58 (2H, m), 2.56 (3H, s), 1.56-1.43 (2H, m), 1.39 (9H, s), 1.35 (3H, t, J = 8 Hz). HPLC: 95%, ret. time = 25 1.627 min., LC/MS (M+H) $^+$ = 577.17.

C83.4: 2-[4-Chloro-8-(2-sulfamoylamino-ethyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester



C83.4


Trifluoroacetic acid (20% solution in dichloromethane, 10 mL) was added in one portion to **C83.3** (100 mg, 0.17 mmol) at room temperature under a nitrogen atmosphere. After stirring overnight, toluene (1 mL) was added and the solution was concentrated in vacuo. Two subsequent additions of toluene (2 x 5 mL) followed by concentration in vacuo left the crude trifluoroacetic acid salt of **C83.4** as a white residue (98mg, 100%). $^1\text{H-NMR}$ (DMSO-d₆) δ : 4.23 (2H, q, $J = 8$ Hz), 3.90-3.84 (2H, m), 3.50-3.46 (2H, m), 3.44-3.40 (2H, m), 2.64-2.58 (2H, m), 2.56 (3H, s), 1.56-1.43 (2H, m), 1.35 (3H, t, $J = 8$ Hz). HPLC: 95%, ret. time = 1.432 min., LC/MS (M+H)⁺ = 476.14.

C83.5: 4-Methyl-2-(4-morpholin-4-yl-8-(2-sulfamoylamino-ethyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino)-thiazole-5-carboxylic acid ethyl ester

Example **C83** was prepared in an analogous manner to Example **C8** from intermediate **C83.4** and morpholine. HPLC: ret. time = 1.63 min. (Phenomenex 5 μm C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% H₃PO₄, 5 mL/min, monitoring at 220 nm or 254 nm), LC/MS (M+H)⁺ = 527.72.




20

Example C84-C86



Examples **C84** to **C86** were prepared in a similar manner to that used for Example **C83** utilizing the appropriate amine replacement for morpholine in step **C83.5**.

Table C3


Ex.	Z	Name	HPLC Retention (min) ^a	MS Reported
C84		2-[4-(2-Acetylamino-ethylamino)-8-(2-sulfamoylamino-ethyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.57	542.71
C85		4-Methyl-2-[4-(3-oxo-piperazin-1-yl)-8-(2-sulfamoylamino-ethyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.58	540.73
C86		2-[4-(4-Hydroxy-piperidin-1-yl)-8-(2-sulfamoylamino-ethyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.56	541.74

^aPhenomenex 5 μ m C18 column 4.6 x 30 mm, 10-90 % aqueous methanol over 2 min containing 0.2% H_3PO_4 , 5 mL/min, monitoring at 220 nm or 254 nm


5

Example D1

2-[8-(4-Methanesulfonyl-benzyl)-4-(3-oxo-piperazin-1-yl)-6,7-dihydro-pyrimido[5,4-b][1,4]oxazin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester


**D1****D1.1: 2-Diazo-malonic acid diethyl ester**

5

**D1.1**

A solution of diethylmalonate (13.9 g, 87 mmol) in acetonitrile (150 ml) at 0-5°C was added triethylamine (10.5 g, 104 mmol), followed by tosyl azide (20.5 g, 104 mmol) in acetonitrile (100ml). The reaction mixture was warmed up to room temperature and stirred for 16 hours which was concentrated to afford a crude product. It was diluted with diethyl ether (100ml) and stirred for 10 minutes. The white solid was removed with filtration. The organic phase was washed with 1 N NaOH solution (50ml), water (50ml), brine (50ml), and dried over sodium sulfate. The solution was filtered through florisil and concentrated *in vacuo*. The crude product mixture was purified by silica gel column chromatography with hexanes:EtOAc (100:15) to yield **D1.1** (16.38 g, 100%). ¹H-NMR (CDCl₃) δ: 4.35 (4H, q, J = 7 Hz), 1.37 (3H, t, J = 7 Hz). HPLC: 92.6%, ret. time = 2.220 min., LC/MS (M+H)⁺ = 187.


20

D1.2: 2-(2,2-Diethoxy-ethoxy)-malonic acid diethyl ester**D1.2**

A solution of **D1.1** (16.3 g, 87.5 mmol), glycolaldehyde diethyl acetal (10.2 g, 76.2 mmol) and rhodium(II) acetate dimer (0.674 g, 1.52 mmol) in toluene (250 ml) was heated to 65°C for 2 hours and then it was cooled to room temperature. The catalyst was removed by filtration. The filtrate was concentrated to yield a crude product which was purified by silica gel column chromatography with hexanes: EtOAc (7:3) to yield **D1.2** (14.86 g, 67%). ¹H-NMR (CDCl₃) δ: 4.79 (1H, s), 4.77 (1H, t, J=5Hz), 4.30-4.40 (4H, m), 3.75-3.84 (4H, m), 3.61-3.69 (2H, m), 1.38 (6H, t, J = 7 Hz), 1.30 (6H, t, J = 7 Hz).


D1.3: 2-[5-(2,2-Diethoxy-ethoxy)-4,6-dihydroxy-pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester

15

**D1.3**

Sodium (2.23 g, 97 mmol) in ethanol (170ml) was stirred at room temperature until the sodium dissolved. The reaction mixture was treated with **A1.1** (7.37 g, 32.3 mmol), followed by **D1.2** (11.8g, 40.4 mmol) and then heated at 100°C for 3 hours. The reaction mixture was cooled to RT and the solid was collected by filtration to afford **D1.3** (14.8 g , 100%). LC/MS (M+H)⁺ = 429.31.


D1.4: 2-[4,6-Dichloro-5-(2,2-diethoxy-ethoxy)-pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester

**D1.4**

To a solution of diisopropylethylamine (5.46 g, 42 mmol) in POCl_3 (12 ml) at 0-5° was added **D1.3** (6 g, 14 mmol) in portions. The reaction mixture was 5 warmed up to room temperature and then it was heated to 100°C for 90 minutes. The reaction mixture was distilled to remove POCl_3 to yield a dark crude product which was added to ice water (100ml) and neutralized with 1 N NaOH to pH 7. The solid was collected to afford **D1.4** (4.97 g, 76%). HPLC: 90%, ret. time = 4.230 min., LC/MS ($\text{M}+\text{H})^+ = 465.07$.

10

D1.5: 2-[4-Chloro-7-hydroxy-8-(4-methanesulfonyl-benzyl)-6,7-dihydro-pyrimido[5,4-b][1,4]oxazin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester



15


D1.5

A solution of **D1.4** (90 mg, 0.194 mmol), 4-methylsulfonylbenzylamine•HCl (45.3 mg, 0.194 mmol) and diisopropylethylamine (56.2 mg, 0.388 mmol) in N-methyl-2-pyrrolidinone (0.5 ml) was heated to 120°C for 15 minutes under 20 microwave irradiation and then it was cooled down to RT. The reaction mixture was treated with 1N HCl solution (0.225 ml, 0.25 mmol), heated to 120°C for 15 minutes under microwave irradiation and then it was neutralized with saturated NaHCO_3 solution and diluted with water (5 ml). The solid was collected by filtration to yield **D1.5** (89 mg, 85%). $^1\text{H-NMR}$ (DMSO-d_6) δ : 11.74 (1H, s), 7.79

(2H, d, J = 8 Hz), 7.58 (2H, d, J = 8 Hz), 6.73 (1H, d, J = 7 Hz), 5.27 (1H, d, J = 16 Hz), 5.02 (1H, d, J = 7 Hz), 4.82 (1H, d, J = 16 Hz), 4.05-4.22 (4H, m), 3.11 (3H, s), 2.40 (3H, s), 1.12 (3H, t, J = 7 Hz). HPLC: 87.4%, ret. time = 3.120 min., LC/MS (M+H)⁺ = 540.02.

5

D1.6: 2-[4-Chloro-8-(4-methanesulfonyl-benzyl)-6,7-dihydro-pyrimido[5,4-b][1,4]oxazin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester



10

D1.6

A solution of **D1.5** (88 mg, 0.163 mmol) and sodium cyanoborohydride (105 mg, 1.59 mmol) in acetic acid (5 ml) was stirred at RT for three days. The reaction mixture was concentrated to yield a crude product which was treated with water (5 ml) and stirred for 5 minutes. The solid was collected by filtration to afford **D1.6** (79.5 mg, 93%). ¹H-NMR (DMSO-d₆) δ : 11.71 (1H, s), 7.83 (2H, d, J = 8 Hz), 7.56 (2H, d, J = 8 Hz), 7.28 (2H, s), 5.03 (1H, s), 4.19-4.25 (2H, m), 4.07 (2H, q, J = 7 Hz), 3.52-3.58 (2H, m), 3.12 (3H, s), 2.40 (3H, s), 1.08 (3H, t, J = 7 Hz). HPLC: 80%, ret. time = 3.367 min., LC/MS (M+H)⁺ = 524.01.

20

D1.7: 2-[8-(4-Methanesulfonyl-benzyl)-4-(3-oxo-piperazin-1-yl)-6,7-dihydro-pyrimido[5,4-b][1,4]oxazin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester

A solution of **D1.6** (20 mg, 0.0381 mmol), piperazin-2-one (16 mg, 0.159 mmol) and diisopropylethylamine (20.4 mg, 0.159 mmol) in N-methyl-2-pyrrolidinone (0.5 ml) was heated to 220°C for 20 minutes under microwave irradiation and then it was cooled down to RT. The reaction mixture was purified by

preparative HPLC to yield **D1** (13 mg, 58 %). ¹H-NMR (DMSO-d₆) δ: 11.14 (1H, s), 7.85 (1H, s), 7.73 (2H, d, J = 8 Hz), 7.44 (2H, d, J = 8 Hz), 4.84 (2H, s), 3.94-4.04 (6H, m), 3.64-3.70 (2H, m), 3.33-3.37 (2H, m), 3.11-3.17 (2H, m), 3.03 (3H, s), 2.31 (3H, s), 1.02 (3H, t, J = 7 Hz). HPLC: >97%, ret. time = 5 3.117 min., LC/MS (M+H)⁺ = 588.07.

Example D2 to D7

Examples **D2** to **D7** were prepared in a similar manner to that used for 10 Example **D1** utilizing the appropriate amine replacements.












Table D


Ex.	Z	R ⁵	Name	HPLC Retention (min) ^a	MS Reported (M+H) ⁺
D2			4-Methyl-2-[4-morpholin-4-yl-8-(3,4,5-trimethoxybenzyl)-6,7-dihydro-pyrimido[5,4-b][1,4]oxazin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	3.65	587.16
D3			4-Methyl-2-[4-morpholin-4-yl-8-(4-sulfamoylbenzyl)-6,7-dihydro-pyrimido[5,4-b][1,4]oxazin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	3.68	576.09

D4			2-[4-(4-Hydroxy-piperidin-1-yl)-8-(4-sulfamoyl-benzyl)-6,7-dihydro-pyrimido[5,4-b][1,4]oxazin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.95	590.08
D5			4-Methyl-2-[4-(3-oxo-piperazin-1-yl)-8-(4-sulfamoyl-benzyl)-6,7-dihydro-pyrimido[5,4-b][1,4]oxazin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	3.01	589.08
D6			2-[8-(4-Methanesulfonyl-benzyl)-4-morpholin-4-yl]-6,7-dihydro-pyrimido[5,4-b][1,4]oxazin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.39	575.09
D7			2-[4-(4-Hydroxy-piperidin-1-yl)-8-(4-methanesulfonyl-benzyl)-6,7-dihydro-pyrimido[5,4-b][1,4]oxazin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	3.08	589.10


^aYMC CombiScreen 5 μ m C18 column 4.6 x 50 mm, 10-90 % aqueous methanol over 4 min containing 0.1% TFA, 4 mL/min, monitoring at 220 nm or 254 nm

Example E1

5 2-[4-(4-Hydroxy-piperidin-1-yl)-9-(3,4,5-trimethoxy-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester

**E1****E1.1: 2-Pent-4-enyl-malonic acid diethyl ester**


5

**E1.1**

A mixture of sodium hydride (60% in mineral oil, 2.4 g, 60.5 mmol, 1.1 eq) and diethyl malonate (8.34 mL, 55 mmol, 1 eq) in DMF (200 mL) was cooled to 0 °C and 5-bromo-1-pentene (6.5 mL, 55 mmol, 1 eq) was added dropwise. The reaction mixture was warmed to rt, stirred for 14 hours and then partitioned between ether and water. The layers were separated, the aqueous layer was extracted with ether (2 x 250 mL) and the combined organic phases were washed with water (2 x) and brine, dried over MgSO₄ and concentrated to give **E1.1** as a colorless oil (12.7 g, 100% yield). ¹H NMR (400 MHz, CDCl₃): δ 5.71 (m, 1 H), 4.92 (m, 2 H), 4.12 (q, *J* = 7.1 Hz, 4 H), 3.25 (t, *J* = 7.58 Hz, 1 H), 2.01 (m, 2 H), 1.83 (m, 2 H), 1.36 (m, 2 H), 1.20 (t, *J* = 7.1 Hz, 6 H).


E1.2: 2-(4,6-Dichloro-5-pent-4-enyl-pyrimidin-2-ylamino)-4-methyl-thiazole-5-carboxylic acid ethyl ester

20

**E1.2**

To a solution of NaOEt in EtOH [prepared by dissolving Na (1.61 g, 70 mmol, 3.5 eq) in 150 mL of absolute ethanol] was added dropwise **E1.1** (5.0 g, 22 mmol, 1.1 eq) and the mixture was stirred at rt for 1 h. **A1.1** (4.54 g, 20 mmol, 1 eq) was added, the reaction mixture was heated at reflux for 16 h and then cooled, concentrated to 1/3 of the original volume, diluted with water (200 mL) and acidified with acetic acid. After stirring for 1h, the solid was collected by filtration, washed with water and dried to afford a light pink solid. The resulting solid was suspended in phosphorous oxychloride (25 mL) and stirred at 95°C for 2 hours. The reaction mixture was poured onto ice, neutralized with NaOH (pellets) and the solid was collected by filtration and vacuum dried to afford **E1.2** as a light brown solid (5.83 g, 66% yield). LC/MS: 401 [M+H]⁺.

E1.3: 2-[4,6-Dichloro-5-(4-oxo-butyl)-pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester




20

E1.3

To a mixture of **E1.2** (2.0 g, 4.98 mmol, 1 eq) and NMO (1.16 g, 9.97 mmol, 2 eq) in THF/water (3:2, 60 mL) at 0 °C was added a solution of OsO₄ in 2-methyl-2-propanol (2.5 wt %, 2.0 mL, 0.19 mmol, 0.04 eq). The reaction mixture was warmed to rt, stirred for 168 h and then quenched with a solution of 500 mg of NaHSO₃ in 30 mL of water, extracted with AcOEt and dried with MgSO₄. The resulting brown solid was dissolved in THF:MeOH (1:1, 60 mL), cooled to 0 °C and treated with Pb(OAc)₄ (1.87 g, 4.21 mmol, 1.1 eq). The resulting mixture was warmed to 23 °C and stirred 18

h, then diluted with ethyl acetate, washed with water and brine, dried over MgSO_4 and concentrated. The residue was purified by flash chromatography (hexane/ethyl acetate 30% to 50%) to yield **E1.3** as a white solid (422 mg, 10% yield). ^1H NMR (400 MHz, DMSO-d_6): δ 9.50 (s, 1 H), 4.07 (q, $J = 7.1$ Hz, 2 H), 2.58 (m, 2 H), 2.39 (m, 2 H), 5 2.35 (s, 3 H), 1.61 (m, 2 H), 1.09 (t, $J = 7.1$ Hz, 3 H). LC/MS: 403 $[\text{M}+\text{H}]^+$.

E1.4: 2-[4-Chloro-9-(3,4,5-trimethoxy-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester



10

E1.4


To a solution of **E1.3** (27 mg, 0.067 mmol, 1.0 eq) and acetic acid (4 μL , 0.067 mmol, 1.0 eq) in THF (3 mL), was added 3,4,5-trimethoxybenzylamine (14 mg, 0.070 mmol, 1.05 eq) and the mixture was stirred for 15 min. Then $\text{Na(OAc)}_3\text{BH}$ 15 (21mg, 0.1 mmol, 1.5 eq) was added and the reaction was stirred at room temperature. After 45 min, it was quenched with NaHCO_3 and extracted with EtOAc , dried MgSO_4 and concentrated in vacuo to yield **E1.4** (37 mg, 100% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6): δ 11.7 (s, 1H), 6.62 (s, 2H), 4.81 (br s, 2H), 4.04 (q, 2H, $J = 7.1$ Hz), 3.65 (s, 6H), 3.56 (s, 3H), 3.46 (m, 2H), 2.79 (m, 2H), 2.42 (s, 3H), 20 1.78 (m, 2H), 1.67 (m, 2H), 1.06 (t, 3H, $J = 7.1$ Hz). LC/MS: 548 $[\text{M}+\text{H}]^+$.

E1.5: 2-[4-(4-Hydroxy-piperidin-1-yl)-9-(3,4,5-trimethoxy-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester

To a solution of **E1.4** (30 mg, 0.055 mmol, 1.0 eq) in NMP (1.5 mL), was added 4-hydroxypiperidine (6.6 mg, 0.066 mmol, 1.2 eq), and triethylamine (10 μ L). The reaction mixture was stirred at 100°C for 7 h and then acidified with acetic acid, purified by Prep HPLC (acetonitrile/water/5mM ammonium acetate, column 5 Primesphere C18 21x100 mm) and freeze dried to give **E1** as a white solid (18 mg, 55% yield). 1 H NMR (400 MHz, DMSO-d₆): δ 11.17 (s, 1H), 6.67 (s, 2H), 4.68 (br s, 2H), 4.66 (d, 1H, J = 4.3 Hz) 4.07 (q, 2H, J = 7.0 Hz), 3.66 (s, 6H), 3.61 (m, 3H), 3.56 (s, 3H), 3.37 (m, 2H), 2.95 (m, 2H), 2.48 (m, 2H), 2.42 (s, 3H), 1.75 (m, 2H), 1.65 (m, 4H), 1.42 (m, 2H), 1.12 (t, 3H, J = 7.0 Hz), HPLC: 100%, ret. time = 2.017 min. (Acetonitrile/water/5mM ammonium acetate, column Primesphere C18 4.6x30 mm), LC/MS: 613 [M+H]⁺.

10











Example E2-E32










15 Examples **E2** to **E32** were prepared in a similar manner to that used for Example **E1** utilizing the appropriate amine replacements.

Table E

Ex.	Z	R ⁵	Name	HPLC Retention (min)	MS Reported (M+H) ⁺
E2			2-[4-(4-Hydroxypiperidin-1-yl)-9-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.68 ^a	602
E3			2-[9-(2-Diisopropylamino-ethyl)-4-(4-hydroxypiperidin-1-yl)-5,6,7,8-tetrahydro-	1.71 ^a	560

			pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester		
E4			2-[4-(4-Hydroxy-piperidin-1-yl)-9-(5-methyl-furan-2-ylmethyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.95 ^a	527
E5			2-[9-[2-(4-Chlorophenyl)-ethyl]-4-(4-hydroxy-piperidin-1-yl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.12 ^a	571
E6			2-[4-(4-Hydroxy-piperidin-1-yl)-9-[2-(4-methoxy-phenyl)-ethyl]-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.00 ^a	567
E7			2-[4-(4-Hydroxy-piperidin-1-yl)-9-indan-1-yl]-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.07 ^a	549
E8			2-[4-(4-Hydroxy-piperidin-1-yl)-9-(4-nitrobenzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.92 ^a	568

E9			2-[9-Cyclohexylmethyl-4-(4-hydroxy-piperidin-1-yl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.16 ^a	529
E10			2-[4-(4-Hydroxy-piperidin-1-yl)-9-phenethyl-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.80 ^b	537
E11			2-[4-(4-Hydroxy-piperidin-1-yl)-9-(4-methanesulfonyl-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.74 ^a	601
E12			2-[4-(4-Hydroxy-piperidin-1-yl)-9-(tetrahydro-furan-2-ylmethyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.81 ^a	517
E13			2-[9-(4-Hydroxycyclohexyl)-4-(4-hydroxy-piperidin-1-yl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.61 ^a	531
E14			2-[9-Furan-2-yl-methyl-4-(4-hydroxy-piperidin-1-yl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid	1.88 ^a	513

			ethyl ester		
E15			2-[9-Cyclohexyl-4-(4-hydroxy-piperidin-1-yl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	2.10 ^a	515
E16			2-[4-(4-Hydroxy-piperidin-1-yl)-9-(2-methoxy-ethyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.75 ^a	491
E17			2-[4-(4-Hydroxy-piperidin-1-yl)-9-thiophen-2-yl-methyl-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.67 ^b	529
E18			2-[4-(4-Hydroxy-piperidin-1-yl)-9-(3-morpholin-4-yl-propyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.22 ^b	560
E19			4-Methyl-2-[4-morpholin-4-yl-9-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.55 ^b	588

E20			4-Methyl-2-[9-(4-sulfamoyl-benzyl)-4-thiomorpholin-4-yl-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.72 ^b	604
E21			2-[4-(3-Hydroxymethyl-piperidin-1-yl)-9-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.52 ^b	616
E22			2-[4-(2,6-Dimethyl-morpholin-4-yl)-9-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.74 ^b	616
E23			2-[4-(4-Acetyl-[1,4]diazepan-1-yl)-9-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.69 ^b	643
E24			4-Methyl-2-[9-(4-sulfamoyl-benzyl)-4-(3,4,5-trimethoxy-benzylamino)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.66 ^b	698
E25			4-Methyl-2-[4-(3-oxo-piperazin-1-yl)-9-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-	1.43 ^b	601

			pyrimido[4,5-b]azepin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester		
E26			4-Methyl-2-[4-morpholin-4-yl-9-(3,4,5-trimethoxy-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.74 ^b	599
E27			4-Methyl-2-[4-thiomorpholin-4-yl-9-(3,4,5-trimethoxy-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.92 ^b	615
E28			2-[4-(3-Hydroxymethyl-piperidin-1-yl)-9-(3,4,5-trimethoxy-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.71 ^b	627
E29			2-[4-(2,6-Dimethyl-morpholin-4-yl)-9-(3,4,5-trimethoxy-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.95 ^b	627
E30			2-[4-(4-Acetyl-[1,4]diazepan-1-yl)-9-(3,4,5-trimethoxy-benzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester	1.89 ^b	654


E31			4-Methyl-2-[9-(3,4,5-trimethoxybenzyl)-4-(3,4,5-trimethoxybenzylamino)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.84 ^b	709
E32			4-Methyl-2-[4-(3-oxo-piperazin-1-yl)-9-(3,4,5-trimethoxybenzyl)-5,6,7,8-tetrahydro-pyrimido[4,5-b]azepin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester	1.59 ^b	612

HPLC conditions used to determine retention times: ^a2 min gradient 0-100% B in A; (A; 0.05% ammonium acetate in 90/10 water/acetonitrile; B; 0.05% ammonium acetate in 10/90 water/acetonitrile) using a Primesphere C-18 4.6x30 mm column at 254 nm. ^b2 min gradient 0-100% B in A; (A; 0.05% TFA in 90/10 water/acetonitrile;

5 B; 0.05%TFA in 10/90 water/acetonitrile) using a Primesphere C-18 4.6x30 mm column at 254 nm

We claim:

1. A compound of Formula (I)



5 (I)

their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein:

R¹ is hydrogen or alkyl;


R² is

10 (a) heteroaryl or heterocyclo, either of which may be optionally independently substituted with one to three groups selected from T¹, T² and/or T³;

(b) aryl substituted with one to three groups selected from T¹, T², and/or T³ provided that at least one of T¹, T² and/or T³ is other than H; or

(c) aryl fused to a heteroaryl or heterocyclo ring forming a fused ring system bound to N* through the aryl wherein the fused ring system may be optionally independently substituted with one to three groups selected from T¹, T² and/or T³;

15 provided that R² is not



20 Z is -NR³R⁴, -NR³SO₂R⁶, OR⁴, SR⁴, haloalkyl or halogen;

J¹ is O, S, S(O), S(O)₂ or optionally substituted C₁₋₃ alkylene;

J² is carbonyl or optionally substituted C₁₋₃ alkylene, provided that J¹ and J² taken together do not form an alkylene chain of greater than 4 carbon atoms;

R^3 and R^4 are independently H, alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or (heterocyclo)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T^4 , T^5 and/or T^6 ;

5 or R^3 and R^4 may be taken together with the nitrogen atom to which they are attached to form a heterocyclo or heteroaryl ring, either of which is optionally independently substituted where valance allows with one to three groups independently selected from T^4 , T^5 and/or T^6 ;

R^5 is

10 (i) H, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be independently substituted where valance allows with one to three groups T^7 , T^8 and/or T^9 ; or
(ii) $-C(O)R^7$, $-C(O)-C(O)-C(O)OR^7$ or $-SO_2R^8$;

15 R^6 is alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo, or (heterocyclo)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T^4 , T^5 and/or T^6 ;

R^7 is

20 (i) H, alkyl, alkenyl, heterocyclo, (heterocyclo)alkyl, (hydroxy)alkyl, (alkoxy)alkyl, (aryloxy)alkyl, heteroaryl, aryl or (aryl)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T^7 , T^8 and/or T^9 ; or
(ii) $-NR^9R^{10}$ or $(NR^9R^{10})alkyl$;

25 R^8 is

(i) alkyl, alkenyl, heterocyclo, (heterocyclo)alkyl, (hydroxy)alkyl, (alkoxy)alkyl, (aryloxy)alkyl, heteroaryl, aryl or (aryl)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T^7 , T^8 and/or T^9 ; or
30 (ii) $-NR^9R^{10}$ or $(NR^9R^{10})alkyl$;

;

R^9 and R^{10} are independently H, alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or (heterocyclo)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T^7 , T^8 and/or T^9 ;

5 T^1 - T^9 are each independently

- (i) alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently substituted by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, 10 oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, $-OT^{10}$, $-SH$, $-ST^{10}$, $-C(O)_tH$, $-C(O)_tT^{10}$, $-O-C(O)T^{10}$, $T^{17}C(O)_tN(T^{11})T^{10}-SO_3H$, $-S(O)_tT^{10}$, $S(O)_tN(T^{11})T^{10}$, $-T^{12}-NT^{14}T^{15}$, $-T^{12}-N(T^{11})-T^{13}-NT^{14}T^{15}$, $-T^{12}-N(T^{16})-T^{15}-T^{10}$ and $-T^{12}-N(T^{16})-T^{13}-H$; or
- (ii) halo, cyano, nitro, OH, oxo, $-SH$, amino, $-OT^{10}$, $-ST^{10}$, $-C(O)_tH$, $-C(O)_tT^{10}$, $-O-C(O)T^{10}$, $T^{17}C(O)_tN(T^{11})T^{10}$, $-SO_3H$, $-S(O)_tT^{10}$, $S(O)_tN(T^{11})T^{10}$, $-T^{12}-NT^{14}T^{15}$, $-T^{12}-N(T^{11})-T^{13}-NT^{14}T^{15}$, $-T^{12}-N(T^{16})-T^{15}-T^{10}$ or $-T^{12}-N(T^{16})-T^{13}-H$;

20 t is 1 or 2;

T^{10} is alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl;

25 T^{12} and T^{13} are each independently a single bond, $-T^{17}-S(O)_t-T^{18}-$, $-T^{17}-C(O)-T^{18}-$, $-T^{17}-C(S)-T^{18}-$, $-T^{17}-O-T^{18}-$, $-T^{17}-S-T^{18}-$, $-T^{17}-O-C(O)-T^{18}-$, $-T^{17}-C(O)_tT^{18}-$, $-T^{17}-C(=NT^{19})-T^{18}-$ or $-T^{17}-C(O)-C(O)-T^{18}-$;

T^{11} , T^{14} , T^{15} , T^{16} and T^{19} are each independently

- (i) hydrogen, alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently

substituted where valence permits by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl, (heteroaryl)alkyl, —SH, —ST²², —C(O)_tH, —C(O)_tT²², —O-C(O)T²² and —S(O)_tT²²; or

5 (ii) halo, cyano, nitro, OH, oxo, —SH, amino, —OT²², —ST²², —C(O)_tH, —C(O)_tT²², —O-C(O)T²², —SO₃H, or —S(O)_tT²²; or

10 (iii) T¹⁴ and T¹⁵ may together be alkylene or alkenylene, completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is substituted with one or more groups listed in the description of T²⁰; or

15 (iv) T¹⁴ or T¹⁵, together with T¹¹, may be alkylene or alkenylene completing a 3- to 8-membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is substituted with one or more groups listed in the description of T²⁰; or

(v) T¹⁴ and T¹⁵ or T¹¹ and T¹⁶ together with the nitrogen atom to which they are attached may combine to form a group —N=CT²⁰T²¹;

20 T¹⁷ and T¹⁸ are each independently a single bond, alkylene, alkenylene or alkynylene; T²⁰ and T²¹ are each

i. independently hydrogen, alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently substituted where valence permits by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl, (heteroaryl)alkyl, —SH, —ST²², —C(O)_tH, —C(O)_tT²², —O-C(O)T²² and —S(O)_tT²²; or

25 ii. halo, cyano, nitro, OH, oxo, —SH, amino, —OT²², —ST²², —C(O)_tH, —C(O)_tT²², —O-C(O)T²², —SO₃H, —S(O)_tT²² or S(O)_tN(T¹¹)T²²; and

30


T^{22} is alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl.

5 2. A compound of claim 1, their enantiomers, diastereomers, and
pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein
 R^2 is

10 (a) heteroaryl optionally independently substituted with one to three groups selected from T^1 , T^2 and/or T^3 ;
(b) aryl substituted with one to three groups selected from T^1 , T^2 , and/or T^3 provided that at least one of T^1 , T^2 and/or T^3 is other than H; or
(c) aryl fused to a heteroaryl or heterocyclo ring forming a fused ring system bound to N^* through the aryl wherein the fused ring system may be optionally independently substituted with one to three groups selected from T^1 , T^2 and/or T^3 .

15

3. A compound of any one of claims 1 to 2, their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R^2 is chosen from:



W is O or S;

Y^1 is $-NHT^{15}$ or OT^{10} ;


25 Y^2 and Y^3 are independently hydrogen, halo, OT¹⁰, alkyl or haloalkyl;

Y^4 is optionally substituted heteroaryl, cyano, $C(O)_tT^{10}$ or $S(O)_tNT^{14}T^{15}$; and

Y^5 is alkyl, haloalkyl, NHT^{15} or OT^{10} .

4. A compound of claim 3, their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein:

R^2 is



W is O or S ;

Y^1 is $-NHT^{15}$ or OT^{10} ; or

Y^2 is alkyl or haloalkyl.

5. A compound of any one of claims 1 to 4, their enantiomers, 10 diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein:

R^1 is H ;

J^1 is O , S or optionally substituted C_1 alkylene;

J^2 is $C(O)$ or optionally substituted $C_{1.3}$ alkylene.;

15 Z is $-NR^3R^4$ or halo;

R^3 is H or alkyl;

R^4 is alkyl, cycloalkyl, heterocyclo, (heteroaryl)alkyl, (heterocyclo)alkyl or

(aryl)alkyl, any of which is optionally independently substituted where valence allows with one to three groups selected from alkyl, hydroxyalkyl,

20 halo, cyano, OH , oxo, cycloalkyl, cycloalkenyl, heterocyclo, heteroaryl, $-C(O)_t$, T^{10} , $-C(O)_tH$, $-NHC(O)T^{10}$, $C(O)N(T^{14})(T^{15})$, OT^{10} , ST^{10} , $S(O)_3H$, $S(O)_tT^{10}$, $S(O)_tN(T^{10})(T^{11})$, $T^{12}N(T^{14})(T^{15})$ and $T^{12}N(T^{16})-T^{15}-T^{10}$;

or R^3 and R^4 may be taken together with the nitrogen atom to which they are attached to form a heterocyclo or heteroaryl ring, either of which may be optionally

25 independently substituted where valence allows with one to three groups selected from alkyl, hydroxyalkyl, halo, cyano, OH , oxo, cycloalkyl, cycloalkenyl, heterocyclo, heteroaryl, $-C(O)_t$ T^{10} , $-C(O)_tH$, $-NHC(O)T^{10}$, $C(O)N(T^{14})(T^{15})$, OT^{10} , ST^{10} , $S(O)_3H$, $S(O)_tT^{10}$, $S(O)_tN(T^{14})(T^{15})$, $T^{12}N(T^{14})(T^{15})$ and $T^{12}N(T^{16})-T^{15}-T^{10}$,


wherein each heterocyclo or heteroaryl is further optionally substituted by one to three groups independently selected from cyano, oxo, hydroxy, alkyl, halo, haloalkyl and $-OT^{10}$;

R^5 is alkyl, cycloalkyl, (cycloalkyl)alkyl, (aryl)alkyl, (heterocyclo)alkyl or (heteroaryl)alkyl, any of which may be optionally independently substituted where valence permits with one to three groups selected from cyano, oxo, hydroxy, alkyl, halo, haloalkyl, $-OT^{10}$, $-C(O)_tN(T^{14})(T^{15})$, $-C(O)_tNH$, $S(O)_t(T^{11})$, $-S(O)_tT^{10}$, $-S(O)_tN(T^{14})(T^{15})$, $T^{12}N(T^{14})(T^{15})$, $-C(O)_tT^{11}$, heterocyclo and heteroaryl,

wherein each heterocyclo or heteroaryl is further optionally substituted by one to three groups selected from cyano, oxo, hydroxy, alkyl, halo, haloalkyl, and $-OT^{10}$.

6. A compound of Formula (Ia)

15



their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein:

20 W is O or S;

Y¹ is $-NHT^{15}$ or OT^{10} ;Y² is alkyl or haloalkyl;Z is $-NR^3R^4$ or halogen;J¹ is O or optionally substituted C₁₋₃ alkylene;25 J² is carbonyl or optionally substituted C₁₋₃ alkylene, provided that J¹ and J² taken together do not form an alkylene chain of greater than 4 carbon atoms;R³ and R⁴ are independently H, alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or

(heterocyclo)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T⁴, T⁵ and/or T⁶;
or R³ and R⁴ may be taken together with the nitrogen atom to which they are attached to form a heterocyclo or heteroaryl ring, either of which is optionally independently substituted where valance allows with one to three groups independently selected from T⁴, T⁵ and/or T⁶;

5 R⁵ is

- (i) H, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be independently substituted where valance allows with one to three groups T⁷, T⁸ and/or T⁹; or
- 10 (ii) -C(O)_tR⁷, -C(O)-C(O)-C(O)OR⁷ or -SO₂R⁸;

15 R⁶ is alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or (heterocyclo)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T⁴, T⁵ and/or T⁶;

R⁷ is

- (i) H, alkyl, alkenyl, heterocyclo, (heterocyclo)alkyl, (hydroxy)alkyl, (alkoxy)alkyl, (aryloxy)alkyl, heteroaryl, aryl or (aryl)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T⁷, T⁸ and/or T⁹; or
- 20 (ii) -NR⁹R¹⁰ or (NR⁹R¹⁰)alkyl;

R⁸ is

- (i) alkyl, alkenyl, heterocyclo, (heterocyclo)alkyl, (hydroxy)alkyl, (alkoxy)alkyl, (aryloxy)alkyl, heteroaryl, aryl or (aryl)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T⁷, T⁸ and/or T⁹; or
- 25 (ii) -NR⁹R¹⁰ or (NR⁹R¹⁰)alkyl;

R⁹ and R¹⁰ are independently H, alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl,

30 (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or (heterocyclo)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T⁷, T⁸ and/or T⁹;

T^1 - T^9 are each independently

5 (i) alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently substituted by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, $-OT^{10}$, $-SH$, $-ST^{10}$, $-C(O)_tH$, $-C(O)_tT^{10}$, $-O-C(O)T^{10}$, $-SO_3H$, $-S(O)_tT^{10}$, $T^{17}C(O)_tN(T^{11})T^{10}$, $S(O)_N(T^{11})T^{10}$, $-T^{12}-NT^{14}T^{15}$, $-T^{12}-N(T^{11})-T^{13}-NT^{14}T^{15}$, $-T^{12}-N(T^{16})-T^{15}-T^{10}$ and $-T^{12}-N(T^{16})-T^{13}-H$; or

10 (ii) halo, cyano, nitro, OH, oxo, $-SH$, amino, $-OT^{10}$, $-ST^{10}$, $-C(O)_tH$, $-C(O)_tT^{10}$, $-O-C(O)T^{10}$, $T^{17}C(O)_tN(T^{11})T^{10}$, $-SO_3H$, $-S(O)_tT^{10}$, $S(O)_tN(T^{11})T^{10}$, $-T^{12}-NT^{14}T^{15}$, $-T^{12}-N(T^{11})-T^{13}-NT^{14}T^{15}$, $-T^{12}-N(T^{16})-T^{15}-T^{10}$ or $-T^{12}-N(T^{16})-T^{13}-H$;

15 t is 1 or 2;

20 T^{10} is alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl;

25 T^{12} and T^{13} are each independently a single bond, $-T^{17}-S(O)_t-T^{18}-$, $-T^{17}-C(O)-T^{18}-$, $-T^{17}-C(S)-T^{18}-$, $-T^{17}-O-T^{18}-$, $-T^{17}-S-T^{18}-$, $-T^{17}-O-C(O)-T^{18}-$, $-T^{17}-C(O)_tT^{18}-$, $-T^{17}-C(=NT^{19})-T^{18}-$ or $-T^{17}-C(O)-C(O)-T^{18}-$;

30 T^{11} , T^{14} , T^{15} , T^{16} and T^{19} are each independently

25 (i) hydrogen, alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently substituted where valence permits by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl,

heteroaryl, (heteroaryl)alkyl, —SH, —ST²², —C(O)_tH, -C(O)T²², —O-C(O)T²² and -S(O)T²² or

5 (ii) halo, cyano, nitro, OH, oxo, -SH, amino, —OT²², —ST²², —C(O)_tH, -C(O)T²², —O-C(O)T²², —SO₃H, -S(O)_tT²² or S(O)_tN(T¹¹)T²²; or

(iii) T¹⁴ and T¹⁵ may together be alkylene or alkenylene, completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is substituted with one or more groups listed in the description of T²⁰; or

10 (iv) T¹⁴ or T¹⁵, together with T¹¹, may be alkylene or alkenylene completing a 3- to 8-membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is substituted with one or more groups listed in the description of T²⁰; or

(v) T¹⁴ and T¹⁵ or T¹¹ and T¹⁶ together with the nitrogen atom to which they are attached may combine to form a group -N=CT²⁰T²¹;

15 T¹⁷ and T¹⁸ are each independently a single bond, alkylene, alkenylene or alkynylene; T²⁰ and T²¹ are each


(i) independently hydrogen, alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl, any of which may be optionally independently substituted where valence permits by one or more groups selected from alkyl, (hydroxy)alkyl, halo, cyano, nitro, OH, oxo, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl, (heteroaryl)alkyl, —SH, —ST²², —C(O)_tH, -C(O)T²², —O-C(O)T²² and -S(O)T²²; or



20 (ii) halo, cyano, nitro, OH, oxo, -SH, amino, —OT²², —ST²², —C(O)_tH, -C(O)T²², —O-C(O)T²², —SO₃H, -S(O)_tT²² or S(O)_tN(T¹¹)T²²; and




25 T²² is alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl or (heteroaryl)alkyl.

30



7. A compound of claim 6, their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein Z is selected from:









5




10





9. A compound of any one of claims 1 to 8 having Formula (II)



their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof,

wherein:

15 Q is O, S or optionally substituted C₁ alkylene; and


X^1, X^2, X^3 and X^4 are

(i) independently chosen from hydrogen, T^{10} , OT^{10} and $NT^{14}T^{15}$; or

(ii) X^1 and X^2 or X^3 and X^4 may be taken together to be a carbonyl group.

20 10. A compound of claim 9, their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein Q is $-\text{CH}_2-$ or O.

11. A compound of any one of claims 1 to 8 having Formula (III)



their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof,


5 wherein:

X^1 , X^2 , X^3 and X^4 are

- (i) independently chosen from hydrogen, T^{10} , OT^{10} or $NT^{14}T^{15}$; and/or
- (ii) either X^1 and X^2 or X^3 and X^4 may be taken together to be a carbonyl group.

10 12. A compound of claim 11, their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X_3 and X_4 are taken together to be a carbonyl group.

13. A compound of any one of claims 1 to 8 having Formula (IV)



IV

15

their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof,

wherein:

20 Q is O, S or optionally substituted C_1 alkylene; and

X^1 , X^2 , X^3 , X^4 , X^5 and X^6 are

- (i) independently chosen from hydrogen, T^{10} , OT^{10} or $NT^{14}T^{15}$; and/or
- (ii) any one of X^1 and X^2 or X^3 and X^4 or X^5 and X^6 may be taken together to be a carbonyl group.

25

14. A compound selected from

i. 2-[7-(4-Methanesulfonyl-benzyl)-4-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[7-(4-Methanesulfonyl-benzyl)-4-methylamino-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]- 4-methyl-thiazole-5-carboxylic acid ethyl ester;

5 2-[7-(3,4-Dimethoxy-benzyl)-4-(3-oxo-piperazin-1-yl)-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-(2-Cyclohex-1-enyl-ethylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

10 2-[4-(Butoxycarbonylmethyl-amino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-Cyclopentylamino-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino)-4-methyl-thiazole-5-carboxylic acid ethyl ester;

15 4-Methyl-2-{4-[(5-methyl-furan-2-ylmethyl)-amino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino }-thiazole-5-carboxylic acid ethyl ester;

20 4-Methyl-2-{4-[3-(2-methyl-piperidin-1-yl)-propylamino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino }-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-{4-[3-(2-methyl-piperidin-1-yl)-propylamino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino }-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-[4-(2-oxo-azepan-3-ylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

5 4-Methyl-2-{7-pyridin-3-ylmethyl-4-[(thiophen-2-ylmethyl)-amino]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester;

2-[4-(3-Imidazol-1-yl-propylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

10 4-Methyl-2-[4-(1-carboxyethyl-piperidin-4-ylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

15 2-[4-(6-Dimethylamino-hexylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-[4-(2-pyridin-4-yl-ethylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

20 2-[4-(4-Hydroxy-butylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-{4-[(1-Ethyl-pyrrolidin-2-ylmethyl)-amino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-(2-Acetyl-amino-ethyl-amino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-{4-[2-(1-methyl-pyrrolidin-2-yl)-ethylamino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester;

2-[4-(1-Hydroxymethyl-butylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-[4-(3-morpholin-4-yl-propylamino)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

2-{4-[2-(1H-Imidazol-4-yl)-ethylamino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-{(S)-2-Carbamoyl-pyrrolidin-1-yl}-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-(3-Hydroxy-pyrrolidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-(4-morpholin-4-yl-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino)-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-{4-[methyl-(1-methyl-piperidin-4-yl)-amino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo [2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester;

2-[4-(3-Diethylcarbamoyl-piperidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-{4-[4-(2-Hydroxy-ethyl)-piperidin-1-yl]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester;

10 4-Methyl-2-{4-[4-(2-oxo-2-pyrrolidin-1-yl-ethyl)-piperazin-1-yl]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester;

2-{4-[4-(Furan-2-carbonyl)-piperazin-1-yl]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester,

15 2-[4-(4-Hydroxy-piperidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-(3-Acetylamino-pyrrolidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

20 2-{4-[Ethyl-(1-ethyl-pyrrolidin-3-yl)-amino]-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-[4-(4-carboxyethyl-piperidin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

2-[4-(4-Acetyl-piperazin-1-yl)-7-pyridin-3-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-{4-[3-(2-oxo-pyrrolidin-1-yl)-propylamino]-7-[4-(1H-tetrazol-5-yl)-benzyl]-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino}-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-(4-morpholin-4-yl-6-oxo-7-pyridin-4-ylmethyl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-2-ylamino)-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-[4-morpholin-4-yl-8-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

4-Methyl-2-[4-methylamino-8-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-thiazole-5-carboxylic acid ethyl ester;

2-[8-(4-Ethanesulfonylamino-benzyl)-4-(3-oxo-piperazin-1-yl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[4-(2-Acetylamino-ethylamino)-8-(4-ethanesulfonylamino-benzyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester;

2-[8-(4-Methanesulfonylaminocarbonyl-benzyl)-4-(3-oxo-piperazin-1-yl)-

5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-4-methyl-

thiazole-5-carboxylic acid ethyl ester;

2-[4-(4-Hydroxy-piperidin-1-yl)-9-(4-sulfamoyl-benzyl)- 5,6,7,8-tetrahydro-

5 pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid

ethyl ester; or

2-[4-(4-Acetyl-[1,4]diazepan-1-yl)-9-(4-sulfamoyl-benzyl)-5,6,7,8-tetrahydro-

pyrimido[4,5-b]azepin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid

ethyl ester; or

10 ii. the enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates of each of (i).

15. A pharmaceutical composition comprising at least one compound of any one of claims 1 to 14.

15

16. The pharmaceutical composition of claim 15 further comprising at least one additional therapeutic agent suitable for the treatment of leukocyte activation-associated diseases.

20

17. The pharmaceutical composition of any one of claims 16 wherein the at least one additional therapeutic agent is selected from PDE4 inhibitors, consisting of NSAIDs, COX-2 inhibitors, TNF- α inhibitors, beta-2 agonists, anti-cholinergic agents, and steroids.

25

18. A method of treating leukocyte activation-associated disorders which comprises administering an effective amount of at least one composition of any one of claims 1 to 14 to a patient in need thereof.

19. The method of claim 18 wherein said disorder is transplant rejection, graft versus host disease, rheumatoid arthritis, multiple sclerosis, juvenile diabetes, asthma, inflammatory bowel disease, ischemic or reperfusion injury, cell proliferation, or psoriasis.